



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed 

Dated 1 September 2003



Patents Form 1/77

Patents Act 1977
(Rule 16)



230CT02 EY57725-1/000192
POL/7700 0100-0224559.5

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference	P.85796 GCW		
2. Patent application number (The Patent Office will fill in this part)	0224559.5		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	OXAGEN LIMITED 3 Worcester Street Oxford OX1 2PZ United Kingdom		
Patents ADP number (if you know it)	7509490001		
If the applicant is a corporate body, give the country/state of its incorporation	UNITED KINGDOM		
4. Title of the invention	TEST		
5. Name of your agent (if you have one)	J.A. KEMP & CO.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	14 South Square Gray's Inn. London WC1R 5JJ		
Patents ADP number (if you know it)	1825001 26001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

Patents Form 1/77:

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 48

Claim(s) 3 DMC

Abstract 1

Drawing(s) 11

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

J.A. KEMP & CO.

Date 22 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

G.C. WOODS
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

TEST

Field of the Invention

The present invention relates to methods of predicting the future health of an individual and of determining the dosage of a glucocorticoid when used as a
5 medicament.

Background to the Invention

Glucocorticoids (GC) exert their effects via the glucocorticoid receptor (GR) and play an important regulatory role in physiology. Several patients have been
10 described with partial forms of GC resistance. They show a wide spectrum of clinical symptoms such as hypertension, hypokalemic alkalosis, fatigue and hyperandrogenism.

Within the normal population there is a considerable amount of variability in the feedback sensitivity of the hypothalamo-pituitary-adrenal (HPA)-axis. The
15 molecular mechanisms underlying this variation in GC-sensitivity are still largely unknown.

In the symptomatic patients with familial forms of glucocorticoid resistance, missense mutations in the ligand binding domain of the glucocorticoid receptor gene causing decreased ligand binding have been described, as well as a deletion of four
20 base pairs at the boundary of exon 6 and intron 6 causing loss of a splice site and a 50% reduction in the number of receptors per cell.

Within the normal population, several polymorphisms in the GR gene have been reported. One of these polymorphisms consists of a point mutation in codon 363 in exon 2 of the GR gene and results in an asparagine to serine amino acid
25 change which is associated with an increased sensitivity to GCs in response to dexamethasone (DEX). Another polymorphism (ER22/23EK) consists of two linked point mutations separated by one base pair in codons 22 and 23 in exon 2 of the GR gene. The first mutation is silent, changing codon 22 from GAG to GAA, both coding for glutamic acid (E). The second mutation changes codon 23 from AGG to
30 AAG, resulting in an amino acid change from arginine (R) to lysine (K) (Koper *et al* Hum. Genet. 1997; 99(5):663-8). These mutations have been shown not to alter the

activity of GR in “*in vitro*” experiments (de Lange *et al.*, Mol. Endocrinol 1997; 11(8):1156-64). The clinical relevance of this polymorphism has not been studied but carriers show a variety of phenotypes ranging from asymptomatic to glucocorticoid resistant (Huizenga *et al.*, J. Clin. Endocrinol. Metab. 2000; 85(5): 2076-81).

Summary of the Invention

The present inventors have investigated, within the context of an ongoing population based cohort study of diseases in the elderly (The Rotterdam Study), whether there are any differences *in vivo* between ER22/23 EK-carriers and non-carriers. They have found, unexpectedly, that there were a significantly higher percentage of ER22/23EK-carriers in the highest age group (age 67-82 years) than in the youngest age group (age 53-67 years) and thus that this GR polymorphism is associated with an increased life expectancy. They also found that after administration of dexamethasone (DEX) the ER22/23EK-carriers had higher serum cortisol concentrations than non-carriers and that ER22/23 EK-carriers had lower insulin levels than non-carriers both before and after DEX. In addition, they found that ER22/23EK-carriers tended to have lower fasting glucose concentrations and that cholesterol concentrations were significantly lower in the ER22/23EK-carriers.

Accordingly, the present invention provides:

- a method of determining the risk of an individual developing a metabolic disorder, the method comprising:
 - (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
 - (ii) determining the likelihood of the individual developing a metabolic disorder, wherein the presence of the ER22/23EK polymorphism is indicative of a low risk of developing the metabolic disorder and the absence of the ER22/23EK polymorphism is indicative of a high risk of developing the metabolic disorder;
- a method of predicting the longevity of an individual, the method comprising:
 - (i) detecting in a sample from the individual the presence or absence of

- the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) determining the life expectancy of the individual, wherein the presence of the ER22/23EK polymorphism is indicative of a long life expectancy;
- 5 - a method of determining the dose of glucocorticoid for administration to an individual in need thereof, the method comprising:
- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) determining whether the dose of glucocorticoid for administration to the individual should be altered compared to the standard dosage, wherein the presence of the ER22/23EK polymorphism indicates that the dosage should be increased;
- 10 - a method of determining whether a treatment regimen is suitable for an individual having a metabolic disorder, the method comprising:
- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) determining whether the treatment is suitable for the individual, wherein the suitability of the treatment depends on the presence or absence of the ER22/23EK polymorphism;
- 15 - a method for diagnosing and treating an individual susceptible to a metabolic disorder, the method comprising:
- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) administering to an individual having the ER22/23KK polymorphism a therapeutically effective amount of an agent which prevents or treats the metabolic disorder;
- 20 - a method for increasing the life expectancy of an individual, the method comprising:
- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) introducing into the individual an allele of the glucocorticoid receptor
- 25
- 30

gene or a glucocorticoid receptor, wherein said gene or polypeptide does not have said polymorphism;

- a method for identifying an agent comprising:

(i) contacting a glucocorticoid receptor polypeptide having the sequence shown in SEQ ID NO: 1 or a fragment thereof which includes the ER22/23EK polymorphism with a test agent;

(ii) monitoring binding of the test agent to the polypeptide; and

(iii) determining whether said test agent may increase life expectancy or be suitable for treating a metabolic disease, wherein for increasing life expectancy or treating a metabolic disease agent is one that binds to the polypeptide; and

- use of a non-human animal which is transgenic for a polynucleotide having the sequence shown in SEQ ID NO: 1 in screening for agents for use in the treatment of a metabolic disorder or for increasing life expectancy.

Brief Description of the Sequences

SEQ ID NO: 1 is the nucleotide sequence of the glucocorticoid receptor cDNA having the ER22/23EK polymorphism. SEQ ID NO: 2 is the amino acid sequence of the glucocorticoid receptor having the ER22/23EK polymorphism.

SEQ ID NO: 3 is the nucleotide sequence of the non-variant allele of the glucocorticoid receptor, i.e. the cDNA sequence not having the ER22/23EK polymorphism. SEQ ID NO: 4 is the amino acid sequence of the glucocorticoid receptor not having the ER22/23EK polymorphism.

Brief Description of the Figures

Figure 1 is a schematic representation of the structure of the human glucocorticoid receptor gene, mRNA and protein showing its functional domains. The position of the arginine to lysine change at codon 23 as a result of the G to A point mutation and the silent point mutation of a G to A at codon 22 are indicated. N-TERM = NH₂-terminal domain; DBD = DNA binding domain and HBD = hormone binding domain.

Detailed Description of the Invention

In the first aspect, the present invention provides a method for determining the risk of an individual developing a metabolic disorder, the method comprising:

- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) determining the likelihood of the individual developing a metabolic disorder, wherein the presence of the ER22/23EK polymorphism is indicative of a low risk of developing the metabolic disorder and the absence of the ER22/23EK polymorphism is indicative of a high risk of developing the metabolic disorder.

The method can be used to assess whether an individual may develop a metabolic disorder in the future. Therefore, the individual may be asymptomatic, ie. may not exhibit any symptoms associated with the metabolic disease, for example, the individual may not show any symptom of glucocorticoid resistance.

The metabolic disease is selected from cardiovascular disease, diabetes mellitus, glucose intolerance/insulin resistance, dyslipidemia (hypercholesterolemia in particular) and (metabolic) Syndrome X.

The metabolic disorder is preferably selected from cardiovascular disease, glucose-intolerance and/or diabetes mellitus.

The glucocorticoid receptor gene and the ER22/23EK polymorphism have been described previously and are shown in SEQ ID NO: 1 (polynucleotide) and SEQ ID NO: 2 (polypeptide).

An individual having the ER22/23EK polymorphism has an adenosine (A) residue at the second position in codon 23 and generally also an adenosine (A) residue at the third position in codon 22 of the glucocorticoid receptor gene (at positions 198 and 200 in SEQ ID NO. 1). Thus an individual having the ER22/23EK polymorphism will have a lysine (K) residue at position 23 of the glucocorticoid receptor amino acid sequence.

The risk of an individual developing a metabolic disease is the likelihood of the individual developing the metabolic disease in the future. The likelihood of developing a metabolic disease is greater in an individual not having a ER22/23EK

polymorphism in the glucocorticoid receptor gene than in an individual having this polymorphism. Thus, detection of the presence of the ER22/23EK polymorphism in a sample from an individual indicates that the individual has a low chance of developing the metabolic disorder and detection of the absence of the ER22/23EK polymorphism constitutes a high risk.

An individual having the ER22/23EK polymorphism has a low risk of developing a metabolic disorder compared to an individual not having the ER22/23EK polymorphism. An individual not having the ER22/23EK polymorphism has a high risk of developing a metabolic disorder compared to an individual having the ER22/23EK polymorphism.

An individual with a low risk of developing a metabolic disorder typically has a 10 to 30%, preferably a 5 to 20 % chance and more preferably a 0 to 15 % chance of developing the disorder. An individual not having the ER22/23EK polymorphism may be considered as being susceptible to a metabolic disorder.

Where it is determined that an individual does not have the ER22/23EK polymorphism, i.e. that the individual has a high risk of developing a metabolic disorder, further tests may be carried out on a sample from the individual and/or the individual may be prescribed a preventative treatment.

For example, the individual's lipid spectrum in the blood (especially total and LDL cholesterol), fasting glucose levels or blood pressure may be tested. The determination of other cardiovascular risk factors, such as smoking, increased weight and positive family history for cardiovascular disease at a relatively young age may be carried out to fully assess the individual's risk profile.

In a second aspect, the present invention provides a method of predicting the life expectancy of an individual by detecting in a sample from the individual the presence of the ER22/23EK polymorphism in the glucocorticoid receptor gene, wherein the presence of the ER22/23EK polymorphism is indicative of a long life expectancy.

Also provided by the invention, is a method for increasing the life expectancy of an individual, the method comprising detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor

gene and introducing into the individual an allele of the glucocorticoid receptor gene or a glucocorticoid receptor polypeptide, which gene or polypeptide does not have the ER22/23EK polymorphism. The gene not having the ER22/23EK polymorphism is typically a polynucleotide which encodes a glucocorticoid receptor having an arginine residue at position 22. A glucocorticoid receptor polypeptide not having the ER22/23EK polymorphism typically has an arginine residue at position 22.

The life expectancy of an individual having the ER22/23EK polymorphism is typically greater than that of an individual not having the ER22/23EK polymorphism. Generally the presence of the ER22/23EK polymorphism in a sample from an individual indicates that the individual is expected to survive to the age of at least 67, 70 or 75 preferably 80 or 85 years of age.

The individual may be of any age, for example, from 15 to 25, 26 to 35, 36 to 45, 46 to 55, 56 to 65 or 66 to 75. Preferably the individual does not show any symptoms of a metabolic disorder.

In a further aspect, the present invention provides a method of determining the dose of glucocorticoid for administration to an individual in need thereof, the method comprising:

- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (ii) determining whether the dose of glucocorticoid for administration to the individual should be altered compared to the standard dosage, wherein the presence of the ER22/23EK polymorphism indicates that the dosage should be increased.

The method may also comprise the further step of administering the glucocorticoid in the required dose, i.e. in a therapeutically effective amount, to the individual.

If the ER22/23EK polymorphism is present then the dose of glucocorticoid required will be raised compared to the normal dose. The normal dose for a particular route of administration is known to a skilled practitioner. A skilled practitioner will also be readily able to determine by how much the dose of

glucocorticoid should be increased in an individual having the ER22/23EK polymorphism.

An individual in need of glucocorticoid administration is typically suffering from a disease which is generally treated by the administration of a glucocorticoid.

- 5 Such diseases include: Allergic diseases such as asthma, atopic dermatitis and anaphylactic shock, autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, polymyalgia rheumatica, temporal arteritis, Graves' ophthalmopathy, autoimmune hemolysis and myasthenia gravis, inflammatory disorders such as Crohn's disease and ulcerative colitis, neoplastic
- 10 diseases such as lymphomas, graft rejection for example following kidney, heart, lung liver or other tissue transplantation, sarcoidosis, vitamin D intoxication, thyroid storm, septic shock, cerebral edema, altitude sickness, chronic bronchitis and emphysema.

Glucocorticoids that are typically administered to treat such diseases include:

- 15 Hydrocortisone, Prednisone, Prednisolone, Methylprednisolone, Triamcinolone, Dexamethasone, Budesonide, Betamethasone and Beclomethasone.

In a further aspect, the present invention provides a method of determining whether a treatment regime is suitable for an individual having a metabolic disorder, the method comprising detecting in a sample from the individual the presence or

20 absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and determining whether the treatment will be suitable for the individual, wherein the suitability of the treatment depends on the presence or absence of the ER22/23EK polymorphism.

- The individual having a metabolic disorder typically exhibits one or more
- 25 symptom associated with a metabolic disorder. Symptoms of cardiovascular disease which may be exhibited include: nycturia; ankle edema, orthopnoea/dyspnoea, intermittent claudicatio, neurological symptoms as a result of stroke, nausea, sweating, unconsciousness and chest pain (and referred pain in left shoulder, jaw, or in between shoulders). Symptoms of diabetes mellitus include: polydipsia, polyuria,
- 30 weight loss, polyphagia, abdominal pain, nausea and vomiting, drowsiness, Kussmaul respirations, dehydration and obesity. In cases of insulin resistance and

dyslipidemia with very high circulating cholesterol levels xanthelasmata can be observed. Additional symptoms of Syndrome X include obesity, hyperlipidemia and hypertension.

The invention also provides a method for diagnosing and treating an individual susceptible to a metabolic disorder, the method comprising:

- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene;
- (ii) administering to an individual having the ER22/23EK polymorphism, a therapeutically effective amount of an agent which prevents or treats the metabolic disorder. The agent may be a glucocorticoid receptor gene polynucleotide or polypeptide which does not have the ER22/23EK polymorphism. The agent may be a glucocorticoid. Other suitable agents may be identified by a screening method of the invention.

A sample used in any one of the methods of the invention typically comprises a bodily fluid of the individual and may be obtained by any suitable method, for example by using a swab, such as a mouth swab. The sample may be a blood, urine, saliva, cheek cell or hair root sample. The sample is generally processed before the method is carried out, for example DNA may be extracted from the sample and used in the method of the invention. The polynucleotide or protein in the sample may be cleaved either physically or chemically (e.g. using a suitable enzyme).

The individual is typically a human. The individual may be male or female.

Detection of polymorphisms

The presence or absence of the polymorphism may be detected using any method that allows the sequence of the glucocorticoid receptor gene at position 3 in codon 22 and/or position 2 in codon 23, or the sequence of the glucocorticoid receptor polypeptide at codon 23 or at codons 22 and 23 to be determined. The detection method may be chosen to determine the presence of the ER22/23EK polymorphism (the variant sequence), the presence of the non-variant sequence or both the variant and non-variant sequence.

The non-variant sequence is a glucocorticoid receptor coding polynucleotide sequence having a G at position 3 of codon 22 and a G at position 2 of codon 23, or a glucocorticoid receptor polypeptide sequence having an arginine residue at position 23. The variant sequence is a glucocorticoid receptor coding polynucleotide having an A at position 2 of codon 23 and/or at position 3 of codon 22, or a glucocorticoid receptor polypeptide having a lysine residue at position 23.

The polymorphism may be detected in the polynucleotide encoding the glucocorticoid receptor or in the glucocorticoid receptor polypeptide. The ER22/23EK polymorphism generally consists of two point mutations in the glucocorticoid receptor polynucleotide. The sequence at either one or both of the positions of the point mutations may be determined.

The presence or absence of the ER22/23EK polymorphism is typically detected by directly determining the presence or absence an allele of the polymorphic sequence in a polynucleotide or protein of the individual.

Thus, a method of the invention may comprise detection of a glucocorticoid receptor polynucleotide sequence having an adenosine (A) residue at the third position in codon 22 and/or an adenosine (A) residue at the second position in codon 23 (i.e. an adenosine residue at position 98 and/or position 100 of SEQ ID NO: 1). A glucocorticoid receptor polynucleotide sequence having a guanosine (G) residue at the third position in codon 22 and/or a guanosine (G) residue at the second position in codon 23 (i.e. a guanosine residue at position 98 and/or position 100 of SEQ ID NO: 1) may also be detected. Both alleles of the polymorphic sequence may be detected in a method of the invention, for example using a quantitative detection method or in a method using differently labelled probes, to determine whether the individual is heterozygous, homozygous for the ER22/23EK polymorphism or homozygous for the non-variant allele.

Where the glucocorticoid receptor protein sequence is used to detect the presence or absence of the ER22/23EK polymorphism, the glucocorticoid receptor sequence, or a fragment thereof, with a lysine residue at position 23 may be detected. Alternatively, the sequence detected may have an arginine residue at position 23. A

method may involve detecting both a sequence comprising a lysine residue at position 23 and a sequence comprising an arginine residue at position 23.

A polynucleotide for detection is typically genomic DNA or mRNA, or a polynucleotide derived from these polynucleotides, such as in a library made using polynucleotide from the individual (e.g. a cDNA library). The processing of the polynucleotide or protein before the carrying out of the method is discussed further below.

Generally, the presence of the polymorphism is determined in a method that comprises contacting a polynucleotide or protein of the individual with a specific binding agent for the polymorphism and determining whether the agent binds to a polymorphism in the polynucleotide or protein, the binding of the agent to the polymorphism indicating that the ER22/23EK polymorphism is present in the sample.

Generally the agent will also bind to flanking nucleotides and amino acids on one or both sides of the polymorphism, for example at least 2, 5, 10, 15 or more flanking nucleotides or amino acids in total or on each side. Generally in the method, determination of the binding of the agent to the polymorphism can be done by determining the binding of the agent to the polynucleotide or protein. However in one embodiment the agent is able to bind the corresponding wild-type sequence by binding the nucleotides or amino acids which flank the polymorphism position, although the manner of binding will be different to the binding of a polynucleotide or protein containing the polymorphism, and this difference will generally be detectable in the method (for example this may occur in sequence specific PCR as discussed below).

In the case where the presence of the polymorphism is being determined in a polynucleotide it may be detected in the double stranded form, but is typically detected in the single stranded form.

The agent may be a polynucleotide (single or double stranded) typically with a length of at least 10 nucleotides, for example at least 15, 20, 30 or more polynucleotides. The agent may be a molecule which is structurally related to polynucleotides that comprises units (such as purines or pyrimidines) able to

participate in Watson-Crick base pairing. The agent may be a polypeptide, typically with a length of at least 10 amino acids, such as at least 20, 30, 50, 100 or more amino acids. The agent may be an antibody (including a fragment of such an antibody which is capable of binding the polymorphism).

5 A polynucleotide agent which is used in the method will generally bind to the polymorphism, and flanking sequence, of the polynucleotide of the individual in a sequence specific manner (e.g. hybridise in accordance with Watson-Crick base pairing) and thus typically has a sequence which is fully or partially complementary to the sequence of the polymorphism and flanking region. The partially
10 complementary sequence is homologous to the fully complementary sequence.

 In one embodiment of the method the agent is as a probe. This may be labelled or may be capable of being labelled indirectly. The detection of the label may be used to detect the presence of the probe on (and hence bound to) the polynucleotide or protein of the individual. The binding of the probe to the
15 polynucleotide or protein may be used to immobilise either the probe or the polynucleotide or protein (and thus to separate it from a composition or solution).

 In one embodiment the polynucleotide or protein of the individual is immobilised on a solid support and then contacted with the probe. The presence of the probe immobilised to the solid support (via its binding to the polymorphism) is
20 then detected, either directly by detecting a label on the probe or indirectly by contacting the probe with a moiety that binds the probe. In the case of detecting a polynucleotide polymorphism the solid support is generally made of nitrocellulose or nylon. In the case of a protein polymorphism the method may be based on an ELISA system.

25 The method may be based on an oligonucleotide ligation assay in which two oligonucleotide probes are used. These probes bind to adjacent areas on the polynucleotide which contains the polymorphism, allowing (after binding) the two probes to be ligated together by an appropriate ligase enzyme. However the presence of single mismatch within one of the probes may disrupt binding and ligation. Thus
30 ligated probes will only occur with a polynucleotide that contains the polymorphism,

and therefore the detection of the ligated product may be used to determine the presence of the polymorphism.

In one embodiment the probe is used in a heteroduplex analysis based system to detect polynucleotide polymorphisms. In such a system when the probe is bound to polynucleotide sequence containing the polymorphism it forms a heteroduplex at the site where the polymorphism occurs (i.e. it does not form a double strand structure). Such a heteroduplex structure can be detected by the use of an enzyme which is single or double strand specific. Typically the probe is an RNA probe and the enzyme used is RNase H which cleaves the heteroduplex region, thus allowing the polymorphism to be detected by means of the detection of the cleavage products.

The method may be based on fluorescent chemical cleavage mismatch analysis which is described for example in PCR Methods and Applications 3, 268-71 (1994) and Proc. Natl. Acad. Sci. 85, 4397-4401 (1998).

In one embodiment the polynucleotide agent is able to act as a primer for a PCR reaction only if it binds a polynucleotide containing the ER22/23EK polymorphism (i.e. a sequence-specific or allele-specific PCR system). The primer may bind to the coding sequence or the complement of the coding sequence. The primer may thus be a fragment of the sequence shown in SEQ ID NO: 1 or may be complementary to a fragment of the sequence shown in SEQ ID NO: 1. Thus a PCR product will only be produced if the polymorphism is present in the polynucleotide of the individual. Thus the presence of the polymorphism may be determined by the detection of the PCR product. Preferably the region of the primer which is complementary to the polymorphism is at or near the 3' end of the primer. In one embodiment of this system the polynucleotide agent will bind to the wild-type sequence but will not act as a primer for a PCR reaction.

Alternatively, the agent may be able to act as a primer for a PCR reaction only if it binds to a sequence not containing the ER22/23EK polymorphism, i.e. to a glucocorticoid receptor polynucleotide sequence comprising guanosine residues at position three of codon 22 and/or position two of codon 23.

The method may be an RFLP based system. This can be used if the presence of the polymorphism in the polynucleotide creates or destroys a restriction site which

is recognised by a restriction enzyme. Thus treatment of a polynucleotide with such a polymorphism will lead to different products being produced compared to the corresponding wild-type sequence. Thus the detection of the presence of particular restriction digest products can be used to determine the presence of the polymorphism.

The presence of the polymorphism may be determined based on the change which the presence of the polymorphism makes to the mobility of the polynucleotide or protein during gel electrophoresis. In the case of a polynucleotide, single-stranded conformation polymorphism (SSCP) analysis may be used. This measures the mobility of the single stranded polynucleotide on a denaturing gel compared to the corresponding wild-type polynucleotide, the detection of a difference in mobility indicating the presence of the polymorphism. Denaturing gradient gel electrophoresis (DDGE) is a similar system where the polynucleotide is electrophoresed through a gel with a denaturing gradient, a difference in mobility compared to the corresponding wild-type polynucleotide indicating the presence of the polymorphism.

The presence of the polymorphism may be determined using a fluorescent dye and quenching agent-based PCR assay such as the Taqman™ PCR detection system. Generally this assay uses an allele specific primer comprising the sequence around, and including, the polymorphism. The specific primer is labelled with a fluorescent dye at its 5' end, a quenching agent at its 3' end and a 3' phosphate group preventing the addition of nucleotides to it. Normally the fluorescence of the dye is quenched by the quenching agent present in the same primer. The allele specific primer is used in conjunction with a second primer capable of hybridising to either allele 5' of the polymorphism.

In the assay, when the allele comprising the polymorphism is present, Taq DNA polymerase adds nucleotides to the non-specific primer until it reaches the specific primer. It then releases nucleotides, the fluorescent dye and quenching agent from the specific primer through its endonuclease activity. The fluorescent dye is therefore no longer in proximity to the quenching agent and fluoresces. In the presence of the allele which does not comprise the polymorphism the mismatch

between the specific primer and template inhibits the endonuclease activity of Taq and the fluorescent dye is not released from the quenching agent. Therefore, by measuring the fluorescence emitted the presence or absence of the polymorphism can be determined.

- 5 In another method of detecting the polymorphism, a polynucleotide comprising the polymorphic region is sequenced across the region which contains the polymorphism to determine the presence of the polymorphism.

Diagnostic kit

- 10 The invention also provides a diagnostic kit that comprises an agent, probe, primer or antibody (including an antibody fragment) capable of detecting the ER22/23EK polymorphism in the glucocorticoid receptor gene or protein and instructions for using the agent, probe, primer or antibody in a method of the invention. The kit may additionally comprise one or more other reagents or instruments which enable any of the embodiments of the method mentioned above to
15 be carried out.

- Such reagents or instruments include one or more of the following: a means to detect the binding of the agent to the polymorphism, a detectable label (such as a fluorescent label), an enzyme able to act on a polynucleotide (typically a polymerase, restriction enzyme, ligase, RNase H or an enzyme which can attach a label to a
20 polynucleotide), suitable buffer(s) (aqueous solutions) for enzyme reagents, PCR primers which bind to regions flanking the polymorphism (e.g. the primers discussed herein), a positive and/or negative control, a gel electrophoresis apparatus, a means to isolate DNA from sample, a means to obtain a sample from the individual (such as swab or an instrument comprising a needle) or a support comprising wells on which
25 detection reactions can be done.

Screening Methods

 In a still further aspect, the present invention provides a method for identifying an agent for increasing life expectancy or treating a metabolic disease, which method comprises:

- (i) contacting a glucocorticoid receptor polypeptide having the sequence shown in SEQ ID NO. 2 or a fragment thereof which includes the ER22/23EK polymorphism with a test agent and
- (ii) monitoring binding of the test agent to the polypeptide; and
5. (iii) determining whether said test agent may increase life expectancy or be suitable for treating a metabolic disease, wherein a suitable agent is one that binds to the polypeptide.

A fragment for use in a method of the invention is typically at least 5 amino acids long, such as at least 10, 15, 20, 50 or 100 amino acids long.

10 The invention also provides the use of a non-human animal which is transgenic for a polynucleotide having the sequence shown in SEQ ID NO. 1 in screening for agents for use in the treatment of a metabolic disorder or for increasing life expectancy.

The transgenic non-human animal is generally a mammal. The transgenic
15 non-human animal is typically of a species commonly used in biomedical research and is preferably a laboratory strain. Suitable animals include non-human primates and rodents. It is preferred that an animal for use in a screening method is a rodent, particularly a mouse, rat, guinea pig, ferret, gerbil or hamster. Most preferably the animal is a mouse.

20 A typical method for identifying an agent for use in the treatment of a metabolic disorder of increasing life expectancy consists essentially of:

- (i) administering a test agent to a non-human animal which is transgenic for a polynucleotide having the sequence shown in SEQ ID NO.1; and
- (ii) monitoring a metabolic process.

25 The method may comprise the further step of sacrificing the animal.

Metabolic processes that may be monitored include pre- and post-DEX cortisol concentration, pre- and post-DEX insulin and/or glucose levels and total or LDL-cholesterol levels.

Suitable candidate agents which may be tested include antibody products (for
30 example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR grafted antibodies). Furthermore, combinatorial libraries,

defined chemical entities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries may also be tested. The candidate agents may be used in an initial screen of, for example, ten substances per administration, and the agents of batches which show an effect on metabolite levels.

5 The term 'agent' is intended to include a single substance and a combination of two, three or more substances. For example, the term agent may refer to a single peptide, a mixture of two or more peptides or a mixture of a peptide and a defined chemical entity.

10 A transgenic non-human animal of the invention may be dosed with the test agent prophylactically or therapeutically on one or more occasions. Typically test agents may be administered bi-weekly, weekly, twice weekly, daily or two, three or more times a day, for example, at hourly or at two, three or four hourly intervals.

 The test agents may be formulated with standard carriers and/or excipients as is routine in the pharmaceutical art, and as fully described in Remington's
15 Pharmaceutical Sciences, Mack Publishing Company, Eastern Pennsylvania 17th Ed. 1985.

 A test agent may be administered by enteral or parenteral routes such as via oral, buccal, anal, intravenous, intra-arterial, intramuscular, intraperitoneal, subcutaneous or other appropriate administration routes. A test agent may be present
20 in the food or drinking water or may be administered using an osmotic minipump.

 Test agents may be administered at any appropriate dosage. A typical dose may be from 0.1 to 50mg per kg of body weight, for example from 0.5 to 30mg per kg of body weight, 1 to 20mg per kg of body weight or 1 to 10mg per kg of body weight.

25 An agent suitable for increasing life expectancy or treating a metabolic disease is one which lowers post-DEX cortisol concentration and increases pre- and post-DEX insulin and/or glucose levels and which increases total cholesterol levels. Preferably, the observed increase or decrease returns the level of the metabolite being monitored back to level comparable to the level observed in the absence of the
30 ER22/23EK polymorphism.

The present invention also provides an agent identified by a method of the invention. An agent identified in the screening method of the invention may be used in the therapeutic or preventative treatment of a metabolic disorder or to increase life expectancy. The condition of a patient having a metabolic disorder can be improved by the administration of a therapeutically effective, non-toxic amount of such an agent. Accordingly, the present invention provides a method of treating a metabolic disorder or increasing life expectancy consisting essentially of administering a therapeutically inactive amount of an agent of the invention to a patient in need thereof.

10 An agent may be formulated with standard pharmaceutically acceptable carriers and/or excipients as it routine in the pharmaceutical art, and as fully described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Eastern Pennyslavana 17th Ed. 1985, the disclosure of which is included herein of its entirely by way of reference. A pharmaceutical composition comprising an agent of the invention and a pharmaceutically effective carrier or diluent is thus provided by
15 the invention.

Compositions and medicaments for use in a method of treating a gastrointestinal disorder may be formulated in dosage form. Medicaments comprising a therapeutic agent identified by a method of the invention may be in a form suitable for administration to a patient, for example in table, capsule or liquid
20 form, or may be in a concentrated form suitable for preparation by a pharmacist.

The formulation of the product for use in preventing or treating the disease will depend upon factors such as the nature of the agent identified and the disease to be prevented or treated. Typically the agent is formulated for use with a pharmaceutically acceptable carrier or diluent. For example it may be formulated for
25 intracranial, parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration. A physician will be able to determine the required route of administration for each particular patient. The pharmaceutical carrier or diluent may be, for example, an isotonic solution.

30 The dose of product may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the

patient to be treated; the route of administration; and the required regimen. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.

5 The following Examples illustrate the invention.

Subjects and Methods

Subjects

A total of 202 human subjects participated in the study. Their age varied
 10 between 53 and 82 years (98 men and 114 women with mean ages of 67.7 ± 0.6 and 65.9 ± 0.6 years, respectively). They were living in a suburb of Rotterdam, The Netherlands. These subjects were participants in the Rotterdam Study, a population-based cohort study (7983 subjects) of the determinants of chronic disabling diseases in the elderly and were selected at random. Subjects with acute, psychiatric or
 15 endocrine diseases, including diabetes mellitus treated with medication were not invited. Compared to all participants of the Rotterdam study, there were no differences in age and gender distribution and cardiovascular risk factors. The subjects gave their written consent to participate in the study, which received the approval of the Medical Ethics Committee of the Erasmus University Medical
 20 School. In order to get more information about the individual variability of the feedback sensitivity of the HPA-axis all 202 subjects were invited for a second DST with a lower dose DEX (0.25 mg) two and a half years later. 149 subjects agreed to participate in this second test (72 men and 77 women).

25 Anthropometric Measurements

Body weight, height and waist to hip ratio of the subjects were measured, and the body mass index (BMI, kg/m^2) was calculated. Blood pressure was measured in sitting position at the right upper arm with a random-zero sphygmomanometer.

30 Dexamethasone suppression tests

The two dexamethasone suppression tests (DST) were performed as described previously (Huizenga *et al*, J.Clin.Endocrinol Metab.1998; 83(1): 47-54). In brief, venous blood was obtained in the morning between 8 and 9 am after an overnight fast for serum cortisol and insulin measurements. Participants were instructed to ingest a tablet of 1 mg (and 0.25 mg, respectively) DEX at 11.00 pm. The next morning fasting blood was drawn by venapuncture at the same time as the previous morning. To check for compliance and possible abnormalities in the metabolism of DEX, the DEX concentration was also measured in a radioimmunoassay using antiserum obtained from IgG Corporation (Nashville, TN). Intra- and interassay variations were below 8.5% and 14.2% respectively.

Hormonal Measurements

Serum cortisol concentrations were determined using RIA-kits obtained from Diagnostics Products Corporation (Los Angeles, CA). Intra- and interassay variations were below 8.0% and 9.5% respectively. Circulating insulin and cortisol binding globulin concentrations were determined using commercially available radioimmunoassays (Medgenix Diagnostics, Brussels, Belgium). Intra- and interassay variations were 8.0% and 13.7% respectively. Estradiol, androstenedione and DHEAS concentrations were determined using RIA-kits obtained from Diagnostics Products Corporation. Intra- and interassay variations; estradiol: 7.0% and 8.1% androstenedione: 8.3% and 9.2%, DHEAS: 5.3% and 7.0% SHBG was assayed with an commercially available immunoradiometric assay (Diagnostics Products Corporation; intra- and interassay variations were 3.6% and 6.9% respectively). Testosterone was measured with a non-commercial radioimmunoassay (intra- and interassay variations 3.6% and 6.9%). Commercially available immunoradiometric assays were used for the measurement of IGF-BP1 (Diagnostic System Laboratories Inc.; intra- and interassay variations 4.0% and 6.0%).

Biochemical Measurements

Glucose, total cholesterol, HDL-cholesterol and triglycerides were measured using standard laboratory methods. Low density lipoprotein (LDL)-cholesterol was

calculated using the following formula: LDL-cholesterol = total cholesterol - ((triglycerides/5) + HDL-cholesterol).

Genetic analysis

5 Restriction fragment length polymorphism and analysis was carried out to determine GR genotypes. DNA was extracted from peripheral blood leukocytes using standard techniques. PCR amplification of the GR gene was carried out employing primer sequences and amplification conditions as described previously (Koper et al., Hum.Genet. 1997; 99(5): 663-8). The PCR-products were digested
10 with 1 U Mnl I (New England Biolabs, Inc) at 37 °C for 1 hour. Mnl I cleaves at 5'-CCTC(N)7-'3 and at 3'-GGAG(N)6-'5. Fragments were visualised with ethidium bromide on a 3% agarose-gel (MP-Boehringer, Manneheim). We re-analysed the 18 heterozygous and 10 wild type samples and found identical genotypes.

Cardiovascular Tests

15 Assessment of carotid intima-media thickness and the presence of atherosclerotic plaques in the carotid artery was performed with ultrasonography of both carotid arteries with a 7.5-MHz linear-array transducer (ATL UltraMarkIV, Advanced Technology Laboratories, Bothwell, WA) as described previously (Bots et al., J Clin Epidemiol 1997;50(7):801-7 and Bots et al., Circulation
20 1997;96(5):1432-7). For each subject mean intima-media thickness (left + right/2) was taken as measure for wall thickness of the distal common carotid artery. The common and internal carotid artery and the carotid bifurcation were both on line and off line (from tapes) evaluated for the presence (yes/no) of atherosclerotic lesions on both the near and the far wall. Plaques were defined as a focal widening relative to
25 adjacent segments, with protrusion into the lumen composed of either only calcified deposits or a combination of calcification and noncalcified material. A total carotid plaque score was defined by summation of the presence of plaques at the left and right side at three locations (score ranging from 0 to 6) (Bots et al., J. Clin. Epidemiol 1997; 50(7):801 and Bots et al., Stroke 1997; 28 (12):2442-7).
30 Measurement of the systolic blood pressure level of the posterior tibial artery at both

the left and right side was performed to evaluate the presence of atherosclerosis in the arteries of the lower extremities (Meijer *et al.*, Arterioscler Thromb Vasc Biol 1998; 352 (9128): 601-5). The ratio of the systolic blood pressure at the ankle to the systolic blood pressure at the arm was calculated for each leg. The lowest ankle-arm index in either leg was used in the analysis (Meijer *et al.*, Arterioscler Thromb Vasc Biol 1998; 18(2): 185-92). Myocardial infarction was diagnosed on the basis of findings on a resting 12-lead electrocardiogram (ACTA Gnosis IV, EsaoteBiomedica) or self-report, which was verified by research physicians (Kors *et al.*, Lancet 1998; 352; 9128:601-5 and de Bruyne *et al.*, J Clin Epidemiol 1997; 50(8): 947-52). The presence of angina pectoris and intermittent claudication was assessed by a Dutch version of the Rose questionnaire (Rose *et al.*, In: WHO: Geneva; 1982; 1982). Cardiovascular disease was defined as the presence of at least one of these three conditions.

15 Statistical analysis

Data were analysed using SPSS for Windows, release 9.0 (SPSS, Chicago, IL). Logarithmic transformations were applied to normalize variables and to minimize the influence of outliers. Differences between the ER22/23EK-carriers and the non-carriers were adjusted for age and tested by NCOVA using the general linear model procedure. A paired samples t-test was used to compare changes in insulin and glucose concentrations before and after the administration of DEX in all subjects. Results are reported as mean \pm SE. Comparison of the frequencies of the genotypes between different age-groups was carried out using a Chi-square test. P values are two-sided throughout and a $p < 0.05$ was considered to be significant.

25

Results

Example 1: Identification of ER22/23EK carriers

Restriction fragment length polymorphism analysis revealed in the study population of 202 subjects a total of 18 individuals (8.9%) who were heterozygous for the polymorphism in codon 22/23 (see also Figure 2). No individuals homozygous for this polymorphism were found in this group. The allele frequency

30

of the variant allele in this group was 4.2%. Genotype distributions did not differ from those expected under Hardy-Weinberg equilibrium conditions. Sexes were equally represented in the group of ER22/23EK-carriers, as well as in the group of non-carriers. The ER22/23EK-carriers were 2.7 years older compared to non-carriers, which did not reach statistical significance (Table 1; $p = 0.07$). However, in the age group between 67 and 82 years the number of ER22/23EK-carriers was higher (12.9%) than in the age group between 53 and 67 ($n = 101$, 4.9% ER22/23EK-carriers; $p = 0.05$). To rule out the influences of differences in age, all parameters were adjusted for age. No significant differences in anthropometric parameters or blood pressure between the groups were present, as shown in Table 1. At the second examination after 2.5 years 149 of the initial 202 individuals participated (74%), 13 of whom were heterozygous for the codon 22/23 polymorphism. Also in this group of ER22/23EK-carriers the sexes were equally represented. The group of non-carriers now consisted of 66 men and 70 women.

Table 1. Anthropometric parameters and blood pressure in non-carriers (n=184) and ER22/23 EK-carriers (n=18) at baseline.

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Age (years)	66.5	0.44	69.2	1.68	0.07
Height (cm)	1.70	0.01	1.69	0.02	0.85
Weight (kg)	74.7	1.15	71.9	1.97	0.69
BMI (kg/m ²)	26.4	0.28	25.4	0.85	0.25
WHR	0.92	0.01	0.94	0.02	0.62
SBP (mmHg)	138.9	1.42	140.2	5.03	0.86
DBP (mmHg)	74.7	0.73	77.1	2.95	0.42

*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed and, with the exception of age, adjusted for age. SE, Standard Error of the mean, BMI, body mass index, WHR, waist to hip ratio, SBP, systolic bloodpressure, DBP, diastolic bloodpressure.

Example 2: Feedback sensitivity of the HPA-axis

Table 2a shows the concentrations of early morning serum cortisol concentrations before and administration of 1 mg DEX, the DEX concentration, and the cortisol suppression in reaction to DEX (Δ cortisol). There were no differences between the non-carriers and the ER22/23EK-carriers in fasting cortisol concentrations, nor in the decrease of serum cortisol concentrations after dexamethasone. However, the cortisol concentrations after the 1 mg DST were significantly higher in ER22/23EK-carriers than in non-carriers (57.9 in ER22/23EK-carriers and 33.3 nmol/l in non-carriers, $p=0.01$). The actual DEX concentrations did not differ in both groups, so the higher post DEX cortisol levels in the ER22/23EK-carriers were not due to differences in the metabolism of DEX. Also fasting cortisol-binding globulin (CBG) levels were not different in ER22/23EK-carriers and in non-carriers.

Table 2b provides the same parameters before and after the administration of 0.25 mg DEX. Again, there were no differences in fasting cortisol or decrease in cortisol. The cortisol concentrations after the administration of 0.25 mg DEX in ER22/23EK-carriers were not different from those in the non-carriers.

Table 2a. Cortisol and DEX concentrations in non-carriers (n=184) and in ER22/23EK-carriers (n=18) before and after 1 mg DEX at first examination.

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Fasting cortisol (nmol/l)	518.4	11.1	562.8	47.3	0.25
PostDEX cortisol (nmol/l)	33.3	4.9	57.9	17.5	0.01
Δ cortisol (nmol/l)	481.4	11.5	504.9	48.3	0.79
DEX (nmol/l)	7.32	0.27	6.63	0.84	0.21

- 5 *Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed and adjusted for age. SE, Standard Error of the mean, DEX, dexamethasone.

Table 2b. Cortisol and DEX concentrations in non-carriers (n=136) and in ER22/23EK-carriers (n=13) before and after 0.25 mg DEX at second examination.

10

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Fasting cortisol (nmol/l)	545.3	12.4	527.2	30.3	0.82
PostDEX cortisol (nmol/l)	259.5	12.4	267.5	31.3	0.60
Δ cortisol (nmol/l)	285.8	13.5	259.7	40.7	0.26
DEX (nmol/l)	2.85	0.13	2.88	0.52	0.71

- 15 *Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed and adjusted for age. SE, Standard Error of the mean, DEX, dexamethasone.

Example 3: Insulin and glucose concentrations

Tables 3a and 3b show the fasting insulin and glucose concentrations before and after the administration of 1 and 0.25 mg DEX, respectively, and the change in insulin levels in response to DEX administration. In order to be certain that only the data from subjects with a normal carbohydrate tolerance were analysed, subjects developing either hyperinsulinaemia or diabetes mellitus after the inclusion in the study (fasting insulin or glucose concentrations above values of 25 mU/l or 7.8 mmol/l, respectively) were excluded from this analysis (17 non-carriers excluded, n=167, and 3 ER22/23EK-carriers excluded, n=15). In all 182 subjects together, a significant increase in insulin concentrations in response to the administration of 1 mg DEX was noted (11.5 ± 5.15 mU/L before, and 17.2 ± 8.41 mU/L after DEX administration, respectively $p < 0.001$). There were no differences in this increase in serum insulin concentrations between the control group and the ER22/23EK-carriers (5.7 ± 0.6 versus 5.5 ± 1.3 mU/L).

The fasting insulin concentrations tended to be lower in ER22/23EK-carriers than in non-carriers ($p = 0.06$). The same applied to the fasting serum insulin levels measured after 1 mg DEX ($p = 0.07$). These differences in post DEX insulin concentrations were not due to differences in DEX concentrations between the two groups. Fasting glucose concentrations were not different between the non-carriers and ER22/23EK-carriers (5.71 ± 0.05 versus 5.69 ± 0.16 mmol/L, respectively).

At second examination, 2.5 years later, the fasting insulin levels in ER22/23EK-carriers were significantly lower than in the non carriers ($p < 0.001$). Insulin levels decreased in the total group of 115 subjects after the administration of 0.25 mg DEX (14.7 ± 0.45 before, and 13.9 ± 0.50 mU/L after DEX administration, respectively, $p = 0.02$). There were no differences in this decrease in insulin levels between the non-carriers and the ER22/23EK-carriers. After the administration of 0.25 mg DEX insulin concentrations were not different in the ER22/23EK-carriers from those in the non-carriers ($p = 0.11$). Glucose concentrations decreased in all subjects in response to 0.25 mg DEX administration (5.6 ± 0.06 mmol/l before, and 5.5 ± 0.05 mmol/l after DST, respectively, $p = 0.004$). Baseline glucose levels tended

- to be lower in the ER22/23EK-carriers than in the non-carriers (5.3 ± 0.20 and 5.6 ± 0.06 mmol/l, respectively; $p=0.07$). After the 0.25 mg DST there were no significant differences in glucose concentrations (ER22/23EK-carriers: 5.3 ± 0.17 versus non-carriers; 5.5 ± 0.05 mmol/l, respectively; $p=0.11$). There were no differences
- 5 between the non-carriers and ER22/23 EK-carriers in change in glucose in response to DEX administration.

Table 3a. Insulin concentrations in non-carriers (n=167) and ER22/23EK-carriers (n=15) before and after 1 mg DEX at first examination

10

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Fasting insulin (mU/l)	11.7	0.40	8.9	1.19	0.06
Post DEX insulin (mU/l)	17.4	0.67	14.4	1.74	0.07
Δ insulin (mU/l)	5.7	0.55	5.5	1.30	0.90
Fasting glucose (mmol/l)	5.71	0.05	5.69	0.16	0.68

Table 3b. Insulin and glucose concentrations in non-carriers (n=105) and ER22/23EK-carriers (n=10) before and after 0.25 mg DEX at second examination.

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Fasting insulin (mU/l)	15.2	0.46	10.0	1.39	<0.001
Post DEX insulin (mU/l)	14.2	0.52	10.0	1.28	0.11
Δ insulin (mU/l)	-0.92	0.38	0.01	0.95	0.56
Fasting glucose (mmol/l)	5.60	0.06	5.30	0.20	0.07

15

*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed and adjusted for age. SE, Standard Error of the mean. Subjects with fasting insulin > 25mU/l or fasting glucose > 7.8 mmol/l were left out of the calculation; 3 ER22/23EK-carriers and 31 non-carriers were left out.

Example 4: Risk Factors for coronary heart disease and diabetes mellitus

In Table 4 serum concentrations of IGF-BP1, cholesterol, HDL-cholesterol and triglycerides are shown. There were no differences between non-carriers and ER22/23EK-carriers in IGF-BP1 levels or in HDL-cholesterol and triglyceride concentrations. However, total cholesterol levels were significantly lower in ER22/23EK-carriers than in non-carriers (6.86 in non-carriers, versus 6.12 mmol/L in ER22/23EK-carriers $p=0.02$). At the second examination after 2.5 years serum cholesterol concentrations were again lower (6.61 in non-carriers, versus 5.64 mmol/L in ER22/23EK-carriers $p=0.01$, not shown in table).

Table 4. Risk factors for coronary heart disease and Diabetes Mellitus at first examination in non-carriers (n=184) and ER22/23EK-carriers (n=18)

	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
IGF-BP ₁ ($\mu\text{g/L}$)	19.3	1.59	18.8	2.91	0.57
Cholesterol (mmol/L)	6.86	0.09	6.12	0.25	0.02
LDL-cholesterol (mmol/L)	5.11	0.08	4.31	0.25	0.01
HDL-cholesterol (mmol/L)	1.36	0.03	1.43	0.14	0.63
Triglycerides (mmol/L)	1.91	0.07	1.93	0.33	0.67

*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed and adjusted for age. SE, Standard Error of the mean. IGF-BP1, insulin-like growth factor-binding protein-1, LDL-cholesterol, low density lipoprotein-cholesterol HDL-cholesterol, high density lipoprotein-cholesterol.

Example 5: Sex hormones

Table 5 shows the fasting concentrations of sex hormones for men and women separately. No differences between the non-carriers and the ER22/23EK-carriers in the concentrations of estradiol, SHBG, androstenedione, DHEA-S or testosterone were detected.

Table 5. Hormones at first examination in male (n=84) and female (n=100) non-carriers and in male (n=10) and female (n=8) ER22/23EK-carriers

Men	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Estradiol (pmol/L)	107.4	20.2	108.0	22.8	0.63
SHBG (nmol/L)	50.74	2.30	44.01	6.74	0.84
Adion (nmol/L)	6.60	0.34	6.26	0.69	0.94
DHEA-S (μmol/L)	4.01	0.27	3.80	0.46	0.76
Testos (nmol/L)	20.2	0.56	21.9	1.70	0.75

Women	Non-carriers		ER22/23EK-carriers		
	Mean	SE	mean	SE	P-value*
Estradiol (pmol/L)	82.38	5.26	79.67	16.26	0.96
SHBG (nmol/L)	57.55	3.18	76.92	16.07	0.21
Adion (nmol/L)	4.46	0.22	4.59	0.78	0.90
DHEA-S (μmol/L)	2.52	0.16	2.42	0.44	0.92
Testos (nmol/L)	1.37	0.06	1.92	0.64	0.49

*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log transformed. SE, Standard Error of the mean SHBG, sex hormone binding globulin, Adion, androstenedione, DHEAS, dehydroepiandrosterone-sulfate, Testos, testosterone

Example 6: Atherosclerosis and cardiovascular disease

Table 6 presents the prevalence of cardiovascular disease and atherosclerosis in non-carriers and ER22/23EK-carriers. A history of myocardial infarction or the presence of angina pectoris or intermittent claudication was defined as cardiovascular disease. In the control-group 33 % had cardiovascular disease, while in the group of the ER22/23EK-carriers 20 % were affected, but this was not statistically significant ($p=0.20$). When tested for each condition separately the differences were not significant either; intermittent claudication: non-carriers 2 (1.1 %) vs ER22/23EK-carriers 0 (0%), $p = 0.90$, angina pectoris: non-carriers 14 (8.0 %) vs ER22/23EK-carriers 1 (5.9 %), $p = 0.79$, myocardial infarction: non-carriers 61 (34 %) vs ER22/23EK-carriers 5 (28 %), $p=0.14$. We found also no difference between the two groups in mean intima-media thickness of the carotid artery (0.76 ± 0.01 mm in the non-carriers and 0.77 ± 0.06 mm in the ER22/23EK-carriers; $p=0.80$) or mean ankle-arm index (1.1 ± 0.02 in the non-carriers and 1.1 ± 0.07 in the ER22/23EK-carriers; $p=0.89$). The genotype distributions of the prevalence of presence of plaques in the carotid artery is also shown in Table 6. The odds ratio for presence of plaques in the carotid artery in ER22/23EK-carriers was 0.42 (95 % CI 0.2-1.1). After adjustment for age this odds ratio decreased and was statistically significant: 0.27 (95 % CI 0.1-0.8). When we carried out an additional adjustment for cholesterol the odds ratio was 0.33 (95 % CI 0.1-1.0).

Table 6. Parameters of atherosclerosis and cardiovascular disease in non-carriers (n=181) and ER22/23EK-carriers (n= 18)

	Non-carriers	ER22/23EK-carriers
Cardiovascular disease*	54 (33%)	3 (20%)
Mean intima-media thickness a. carotis (mm)	0.76 ± 0.01	0.77 ± 0.06
Mean ankle-arm index	1.09 ± 0.02	1.09 ± 0.07
Presence of plaques in the a.carotis	119 (66%)	8 (44%)
<i>Odds Ratio</i>	1 (reference)	0.27 (0.1-0.8)
Presence of plaques in the a.carotis	1 (reference)	0.33 (0.1-1.0)

5 Values are means +/- standard errors or number of subjects (%). Relative risk is given with a 95 % confidence interval.

^a reference group; subjects homozygous for 22/23ER allele (wild type), adjusted for age, ^b adjusted for age and cholesterol

*History of myocardial infarction or presence of angina pectoris or intermittent claudication. a.

10 carotis, carotid artery

Discussion

In this population study in the elderly involving 202 individuals we found 18 subjects who were heterozygous for the ER22/23EK polymorphism (8.9%). The ER22/23EK-carriers had higher serum concentrations of cortisol after the administration of 1 mg DEX than non-carriers. Furthermore, ER22/23EK-carriers tended to have lower insulin levels before and after a 1 mg DST. These data were partially confirmed two and a half years later with a 0.25 mg DST. Fasting insulin concentrations were again lower in ER22/23EK-carriers and fasting glucose levels tended to be lower in ER22/23EK-carriers as well. These observations suggest that this polymorphism in the GR gene is associated with a slight resistance of the feedback regulation of the HPA-axis.

This relative resistance also results in a lower effect of cortisol on glucose metabolism, resulting in slightly lower glucose concentrations, as well as lower insulin

levels. This rather beneficial metabolic profile is supported by the observation that total serum cholesterol concentrations were significantly lower in the ER22/23EK group than in the group of non-carriers. This was confirmed at the second examination. These outcomes of a relative GC resistance, together with the lower insulin, total cholesterol and slightly lower serum glucose concentrations, indicate that ER22/23EK-carriers have a healthier metabolic profile than non-carriers. Indeed, the relative risk of presence of atherosclerotic plaques in the carotid artery was significantly lower in ER22/23EK-carriers than in non-carriers when adjusted for age. After an additional adjustment for cholesterol this significance disappeared, which indicates that the lower cholesterol levels explain most of the lower risk on the presence of plaques in the carotid artery. In this respect, the fact that we found in the present study a significantly higher percentage of ER22/23EK-carriers in the older age group supports the finding of a beneficial metabolic effect of this GR polymorphism in codon 22 and 23.

We found no other differences between the genotypes in anthropometric parameters, blood pressure, and serum levels of IGF-BP1, HDL-cholesterol, triglycerides or sex hormones.

In summary, in this study we observed that subjects who were heterozygous for the 22/23EK allele had significantly higher post DEX cortisol concentrations, lower insulin and slightly lower glucose levels before the administration of DEX, as well as slightly lower post Dex insulin levels than subjects without this GR variant. Furthermore, ER22/23EK-carriers had lower total cholesterol levels and were overrepresented in the older age group. These data suggest that ER22/23EK-carriers are relatively more 'cortisol-resistant' than non-carriers, which results in a better metabolic health profile.

SEQUENCE LISTING

<110> OXAGEN LIMITED

<120> TEST

<130> P85796 GCW

<160> 4

<170> PatentIn version 3.0

<210> 1

<211> 4788

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (133)..(2466)

<400> 1

tttttagaaa aaaaaaatat atttccctcc tgctccttct gcgttcacaa gctaagttgt	60
---	----

ttatctcggc tgccggcggga actgcggacg gtggcgggcg agcggctcct ctgccagagt	120
--	-----

tgatattcac tg atg gac tcc aaa gaa tca tta act cct ggt aga gaa gaa	171
Met Asp Ser Lys Glu Ser Leu Thr Pro Gly Arg Glu Glu	
1 5 10	

aac ccc agc agt gtg ctt gct cag gaa aag gga gat gtg atg gac ttc	219
Asn Pro Ser Ser Val Leu Ala Gln Glu Lys Gly Asp Val Met Asp Phe	
15 20 25	

tat aaa acc cta aga gga gga gct act gtg aag gtt tct gcg tct tca	267
Tyr Lys Thr Leu Arg Gly Gly Ala Thr Val Lys Val Ser Ala Ser Ser	
30 35 40 45	

ccc tca ctg gct gtc gct tct caa tca gac tcc aag cag cga aga ctt	315
Pro Ser Leu Ala Val Ala Ser Gln Ser Asp Ser Lys Gln Arg Arg Leu	
50 55 60	

ttg gtt gat ttt cca aaa ggc tca gta agc aat gcg cag cag cca gat	363
Leu Val Asp Phe Pro Lys Gly Ser Val Ser Asn Ala Gln Gln Pro Asp	
65 70 75	

ctg tcc aaa gca gtt tca ctc tca atg gga ctg tat atg gga gag aca	411
Leu Ser Lys Ala Val Ser Leu Ser Met Gly Leu Tyr Met Gly Glu Thr	
80 85 90	

gaa aca aaa gtg atg gga aat gac ctg gga ttc cca cag cag ggc caa	459
Glu Thr Lys Val Met Gly Asn Asp Leu Gly Phe Pro Gln Gln Gly Gln	
95 100 105	

atc agc ctt tcc tcg ggg gaa aca gac tta aag ctt ttg gaa gaa agc	507
Ile Ser Leu Ser Ser Gly Glu Thr Asp Leu Lys Leu Leu Glu Glu Ser	

110	115	120	125	
att gca aac ctc aat agg tgc acc agt gtt cca gag aac ccc aag agt				555
Ile Ala Asn Leu Asn Arg Ser Thr Ser Val Pro Glu Asn Pro Lys Ser				
	130	135	140	
tca gca tcc act gct gtg tct gct gcc ccc aca gag aag gag ttt cca				603
Ser Ala Ser Thr Ala Val Ser Ala Ala Pro Thr Glu Lys Glu Phe Pro				
	145	150	155	
aaa act cac tct gat gta tct tca gaa cag caa cat ttg aag ggc cag				651
Lys Thr His Ser Asp Val Ser Ser Glu Gln Gln His Leu Lys Gly Gln				
	160	165	170	
act ggc acc aac ggt ggc aat gtg aaa ttg tat acc aca gac caa agc				699
Thr Gly Thr Asn Gly Gly Asn Val Lys Leu Tyr Thr Thr Asp Gln Ser				
	175	180	185	
acc ttt gac att ttg cag gat ttg gag ttt tct tct ggg tcc cca ggt				747
Thr Phe Asp Ile Leu Gln Asp Leu Glu Phe Ser Ser Gly Ser Pro Gly				
	190	195	200	205
aaa gag acg aat gag agt cct tgg aga tca gac ctg ttg ata gat gaa				795
Lys Glu Thr Asn Glu Ser Pro Trp Arg Ser Asp Leu Leu Ile Asp Glu				
	210	215	220	
aac tgt ttg ctt tct cct ctg gcg gga gaa gac gat tca ttc ctt ttg				843
Asn Cys Leu Leu Ser Pro Leu Ala Gly Glu Asp Asp Ser Phe Leu Leu				
	225	230	235	
gaa gga aac tgc aat gag gac tgc aag cct ctc att tta ccg gac act				891
Glu Gly Asn Ser Asn Glu Asp Cys Lys Pro Leu Ile Leu Pro Asp Thr				
	240	245	250	
aaa ccc aaa att aag gat aat gga gat ctg gtt ttg tca agc ccc agt				939
Lys Pro Lys Ile Lys Asp Asn Gly Asp Leu Val Leu Ser Ser Pro Ser				
	255	260	265	
aat gta aca ctg ccc caa gtg aaa aca gaa aaa gaa gat ttc atc gaa				987
Asn Val Thr Leu Pro Gln Val Lys Thr Glu Lys Glu Asp Phe Ile Glu				
	270	275	280	285
ctc tgc acc cct ggg gta att aag caa gag aaa ctg ggc aca gtt tac				1035
Leu Cys Thr Pro Gly Val Ile Lys Gln Glu Lys Leu Gly Thr Val Tyr				
	290	295	300	
tgt cag gca agc ttt cct gga gca aat ata att ggt aat aaa atg tct				1083
Cys Gln Ala Ser Phe Pro Gly Ala Asn Ile Ile Gly Asn Lys Met Ser				
	305	310	315	
gcc att tct gtt cat ggt gtg agt acc tct gga gga cag atg tac cac				1131
Ala Ile Ser Val His Gly Val Ser Thr Ser Gly Gly Gln Met Tyr His				
	320	325	330	
tat gac atg aat aca gca tcc ctt tct caa cag cag gat cag aag cct				1179
Tyr Asp Met Asn Thr Ala Ser Leu Ser Gln Gln Gln Asp Gln Lys Pro				
	335	340	345	

att ttt aat gtc att cca cca att ccc gtt ggt tcc gaa aat tgg aat Ile Phe Asn Val Ile Pro Pro Ile Pro Val Gly Ser Glu Asn Trp Asn 350 355 360 365	1227
agg tgc caa gga tct gga gat gac aac ttg act tct ctg ggg act ctg Arg Cys Gln Gly Ser Gly Asp Asp Asn Leu Thr Ser Leu Gly Thr Leu 370 375 380	1275
aac ttc cct ggt cga aca gtt ttt tct aat ggc tat tca agc ccc agc Asn Phe Pro Gly Arg Thr Val Phe Ser Asn Gly Tyr Ser Ser Pro Ser 385 390 395	1323
atg aga cca gat gta agc tct cct cca tcc agc tcc tca aca gca aca Met Arg Pro Asp Val Ser Ser Pro Pro Ser Ser Ser Thr Ala Thr 400 405 410	1371
aca gga cca cct ccc aaa ctc tgc ctg gtg tgc tct gat gaa gct tca Thr Gly Pro Pro Pro Lys Leu Cys Leu Val Cys Ser Asp Glu Ala Ser 415 420 425	1419
gga tgt cat tat gga gtc tta act tgt gga agc tgt aaa gtt ttc ttc Gly Cys His Tyr Gly Val Leu Thr Cys Gly Ser Cys Lys Val Phe Phe 430 435 440 445	1467
aaa aga gca gtg gaa gga cag cac aat tac cta tgt gct gga agg aat Lys Arg Ala Val Glu Gly Gln His Asn Tyr Leu Cys Ala Gly Arg Asn 450 455 460	1515
gat tgc atc atc gat aaa att cga aga aaa aac tgc cca gca tgc cgc Asp Cys Ile Ile Asp Lys Ile Arg Arg Lys Asn Cys Pro Ala Cys Arg 465 470 475	1563
tat cga aaa tgt ctt cag gct gga atg aac ctg gaa gct cga aaa aca Tyr Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr 480 485 490	1611
aag aaa aaa ata aaa gga att cag cag gcc act aca gga gtc tca caa Lys Lys Lys Ile Lys Gly Ile Gln Gln Ala Thr Thr Gly Val Ser Gln 495 500 505	1659
gaa acc tct gaa aat cct ggt aac aaa aca ata gtt cct gca acg tta Glu Thr Ser Glu Asn Pro Gly Asn Lys Thr Ile Val Pro Ala Thr Leu 510 515 520 525	1707
cca caa ctc acc cct acc ctg gtg tca ctg ttg gag gtt att gaa cct Pro Gln Leu Thr Pro Thr Leu Val Ser Leu Leu Glu Val Ile Glu Pro 530 535 540	1755
gaa gtg tta tat gca gga tat gat agc tct gtt cca gac tca act tgg Glu Val Leu Tyr Ala Gly Tyr Asp Ser Ser Val Pro Asp Ser Thr Trp 545 550 555	1803
agg atc atg act acg ctc aac atg tta gga ggg cgg caa gtg att gca Arg Ile Met Thr Thr Leu Asn Met Leu Gly Gly Arg Gln Val Ile Ala 560 565 570	1851

gca gtg aaa tgg gca aag gca ata cca ggt ttc agg aac tta cac ctg Ala Val Lys Trp Ala Lys Ala Ile Pro Gly Phe Arg Asn Leu His Leu 575 580 585	1899
gat gac caa atg acc cta ctg cag tac tcc tgg atg ttt ctt atg gca Asp Asp Gln Met Thr Leu Leu Gln Tyr Ser Trp Met Phe Leu Met Ala 590 595 600 605	1947
ttt gct ctg ggg tgg aga tca tat aga caa tca agt gca aac ctg ctg Phe Ala Leu Gly Trp Arg Ser Tyr Arg Gln Ser Ser Ala Asn Leu Leu 610 615 620	1995
tgt ttt gct cct gat ctg att att aat gag cag aga atg act cta ccc Cys Phe Ala Pro Asp Leu Ile Ile Asn Glu Gln Arg Met Thr Leu Pro 625 630 635	2043
tgc atg tac gac caa tgt aaa cac atg ctg tat gtt tcc tct gag tta Cys Met Tyr Asp Gln Cys Lys His Met Leu Tyr Val Ser Ser Glu Leu 640 645 650	2091
cac agg ctt cag gta tct tat gaa gag tat ctc tgt atg aaa acc tta His Arg Leu Gln Val Ser Tyr Glu Glu Tyr Leu Cys Met Lys Thr Leu 655 660 665	2139
ctg ctt ctc tct tca gtt cct aag gac ggt ctg aag agc caa gag cta Leu Leu Leu Ser Ser Val Pro Lys Asp Gly Leu Lys Ser Gln Glu Leu 670 675 680 685	2187
ttt gat gaa att aga atg acc tac atc aaa gag cta gga aaa gcc att Phe Asp Glu Ile Arg Met Thr Tyr Ile Lys Glu Leu Gly Lys Ala Ile 690 695 700	2235
gtc aag agg gaa gga aac tcc agc cag aac tgg cag cgg ttt tat caa Val Lys Arg Glu Gly Asn Ser Ser Gln Asn Trp Gln Arg Phe Tyr Gln 705 710 715	2283
ctg aca aaa ctc ttg gat tct atg cat gaa gtg gtt gaa aat ctc ctt Leu Thr Lys Leu Leu Asp Ser Met His Glu Val Val Glu Asn Leu Leu 720 725 730	2331
aac tat tgc ttc caa aca ttt ttg gat aag acc atg agt att gaa ttc Asn Tyr Cys Phe Gln Thr Phe Leu Asp Lys Thr Met Ser Ile Glu Phe 735 740 745	2379
ccc gag atg tta gct gaa atc atc acc aat cag ata cca aaa tat tca Pro Glu Met Leu Ala Glu Ile Ile Thr Asn Gln Ile Pro Lys Tyr Ser 750 755 760 765	2427
aat gga aat atc aaa aaa ctt ctg ttt cat caa aag tga ctgccttaat Asn Gly Asn Ile Lys Lys Leu Leu Phe His Gln Lys 770 775	2476
aagaatgggtt gccttaaaga aagtcgaatt aatagctttt attgtataaa ctatcagttt	2536
gtcctgtaga gggtttgttg tttttttttt tattgttttc atctgttggtt ttgttttaaa	2596
tacgcactac atgtggttta tagagggccca agacttggca acagaagcag ttgagtcgtc	2656

atcacttttc agt gat gga gag tag atg tga aatttat tagttaatat atcccagaaa	2716
ttagaaacct taatatgtgg acgtaatctc cacagtcaaa gaaggatggc acctaaacca	2776
ccagtgccca aagtctgtgt gatgaacttt ctcttcatac tttttttcac agttggctgg	2836
atgaaatttt ctagactttc tgttggtgta tccccccct gtatagttag gatagcattt	2896
ttgatttatg catggaaacc tgaaaaaaag tttacaagtg tatatcagaa aagggaagtt	2956
gtgcctttta tagctattac tgtctggttt taacaatttc ctttatattt agtgaactac	3016
gcttgctcat tttttcttac ataatttttt attcaagtta ttgtacagct gtttaagatg	3076
ggcagctagt tcttagcttt cccaaataaa ctctaaacat taatcaatca tctgtgtgaa	3136
aatgggttg tgccttctaac ctgatggcac ttagctatca gaagaccaca aaaattgact	3196
caaatctcca gtattcttgt caaaaaaaaa aaaaaaaaaag ctcatatttt gtatatatct	3256
gcttcagtgg agaattatat aggttggtgca aattaacagt cctaactggg atagagcacc	3316
tagtccagtg acctgctggg taaactgtgg atgatgggtg caaaagacta atttaaaaaa	3376
taactaccaa gaggcctgt ctgtacctaa cgcctattt ttgcaatggc tatatggcaa	3436
gaaagctggg aaactatttg tctttcagga ccttttgaag tagtttgtat aacttcttaa	3496
aagttgtgat tccagataac cagctgtaac acagctgaga gacttttaat cagacaaagt	3556
aattcctctc actaaacttt acccaaaaac taaatctcta atatggcaaa aatggctaga	3616
caccattttt cacattccca tctgtcacca attggttaat ctttcctgat ggtacaggaa	3676
agctcagcta ctgatttttg tgatttagaa ctgtatgtca gacatccatg tttgtaaaac	3736
tacacatccc taatgtgtgc catagagttt aacacaagtc ctgtgaattt cttcactggt	3796
gaaaattatt ttaaacaaaa tagaagctgt agtagccctt tctgtgtgca ccttaccaac	3856
tttctgtaaa ctcaaaactt aacatattta ctaagccaca agaaatttga tttctattca	3916
aggtggccaa attatttttg taatagaaaa ctgaaaatct aatattaaaa atatggaact	3976
tctaataatat ttttatattt agttatagtt tcagatatat atcatattgg tattcactaa	4036
tctgggaagg gaagggtac tgcagcttta catgcaattt attaaaatga ttgtaaaata	4096
gcttgatatag tgtaaaataa gaatgatttt tagatgagat tgttttatca tgacatgtta	4156
tatatTTTTT gtaggggtca aagaaatgct gatggataac ctatatgatt tatagtttgt	4216
acatgcattc atacaggcag cgatgggtctc agaaaccaa cagtttgctc taggggaaga	4276
gggagatgga gactggctct gtgtgcagtg aaggttgctg aggcctctgac ccagtgagat	4336

tacagaggaa gttatcctct gcctccatt ctgaccaccc ttctcattcc aacagtgagt 4396
 ctgtcagcgc aggtttagtt tactcaatct ccccttgac taaagtatgt aaagtatgta 4456
 aacaggagac aggaaggtgg tgcttacatc cttaaaggca ccatctaata gcgggttact 4516
 ttacataca gccctcccc agcagttgaa tgacaacaga agcttcagaa gtttggcaat 4576
 agtttgcata gaggtaccag caatatgtaa ataagtgcaga atctcatagg ttgccaataa 4636
 tacactaatt cctttctatc ctacaacaag agtttatttc caaataaaat gaggacatgt 4696
 ttttgttttc tttgaatgct ttttgaatgt tatttgttat tttcagtatt ttggagaaat 4756
 tatttaataa aaaaacaatc atttgctttt tg 4788

<210> 2

<211> 777

<212> PRT

<213> Homo sapiens

<400> 2

Met Asp Ser Lys Glu Ser Leu Thr Pro Gly Arg Glu Glu Asn Pro Ser
 1 5 10 15

Ser Val Leu Ala Gln Glu Lys Gly Asp Val Met Asp Phe Tyr Lys Thr
 20 25 30

Leu Arg Gly Gly Ala Thr Val Lys Val Ser Ala Ser Ser Pro Ser Leu
 35 40 45

Ala Val Ala Ser Gln Ser Asp Ser Lys Gln Arg Arg Leu Leu Val Asp
 50 55 60

Phe Pro Lys Gly Ser Val Ser Asn Ala Gln Gln Pro Asp Leu Ser Lys
 65 70 75 80

Ala Val Ser Leu Ser Met Gly Leu Tyr Met Gly Glu Thr Glu Thr Lys
 85 90 95

Val Met Gly Asn Asp Leu Gly Phe Pro Gln Gln Gly Gln Ile Ser Leu
 100 105 110

Ser Ser Gly Glu Thr Asp Leu Lys Leu Leu Glu Glu Ser Ile Ala Asn
 115 120 125

Leu Asn Arg Ser Thr Ser Val Pro Glu Asn Pro Lys Ser Ser Ala Ser
 130 135 140

Thr Ala Val Ser Ala Ala Pro Thr Glu Lys Glu Phe Pro Lys Thr His
 145 150 155 160

Ser Asp Val Ser Ser Glu Gln Gln His Leu Lys Gly Gln Thr Gly Thr
 165 170 175

Asn Gly Gly Asn Val Lys Leu Tyr Thr Thr Asp Gln Ser Thr Phe Asp

				180				185				190			
Ile	Leu	Gln	Asp	Leu	Glu	Phe	Ser	Ser	Gly	Ser	Pro	Gly	Lys	Glu	Thr
		195					200					205			
Asn	Glu	Ser	Pro	Trp	Arg	Ser	Asp	Leu	Leu	Ile	Asp	Glu	Asn	Cys	Leu
		210				215					220				
Leu	Ser	Pro	Leu	Ala	Gly	Glu	Asp	Asp	Ser	Phe	Leu	Leu	Glu	Gly	Asn
		225			230					235					
Ser	Asn	Glu	Asp	Cys	Lys	Pro	Leu	Ile	Leu	Pro	Asp	Thr	Lys	Pro	Lys
				245					250						
Ile	Lys	Asp	Asn	Gly	Asp	Leu	Val	Leu	Ser	Ser	Pro	Ser	Asn	Val	Thr
			260					265							
Leu	Pro	Gln	Val	Lys	Thr	Glu	Lys	Glu	Asp	Phe	Ile	Glu	Leu	Cys	Thr
		275					280								
Pro	Gly	Val	Ile	Lys	Gln	Glu	Lys	Leu	Gly	Thr	Val	Tyr	Cys	Gln	Ala
		290				295					300				
Ser	Phe	Pro	Gly	Ala	Asn	Ile	Ile	Gly	Asn	Lys	Met	Ser	Ala	Ile	Ser
		305			310					315					
Val	His	Gly	Val	Ser	Thr	Ser	Gly	Gly	Gln	Met	Tyr	His	Tyr	Asp	Met
				325					330						
Asn	Thr	Ala	Ser	Leu	Ser	Gln	Gln	Gln	Asp	Gln	Lys	Pro	Ile	Phe	Asn
			340					345							
Val	Ile	Pro	Pro	Ile	Pro	Val	Gly	Ser	Glu	Asn	Trp	Asn	Arg	Cys	Gln
		355					360								
Gly	Ser	Gly	Asp	Asp	Asn	Leu	Thr	Ser	Leu	Gly	Thr	Leu	Asn	Phe	Pro
		370				375					380				
Gly	Arg	Thr	Val	Phe	Ser	Asn	Gly	Tyr	Ser	Ser	Pro	Ser	Met	Arg	Pro
		385			390					395					
Asp	Val	Ser	Ser	Pro	Pro	Ser	Ser	Ser	Ser	Thr	Ala	Thr	Thr	Gly	Pro
				405					410						
Pro	Pro	Lys	Leu	Cys	Leu	Val	Cys	Ser	Asp	Glu	Ala	Ser	Gly	Cys	His
			420					425							
Tyr	Gly	Val	Leu	Thr	Cys	Gly	Ser	Cys	Lys	Val	Phe	Phe	Lys	Arg	Ala
		435					440					445			
Val	Glu	Gly	Gln	His	Asn	Tyr	Leu	Cys	Ala	Gly	Arg	Asn	Asp	Cys	Ile
		450				455					460				
Ile	Asp	Lys	Ile	Arg	Arg	Lys	Asn	Cys	Pro	Ala	Cys	Arg	Tyr	Arg	Lys
		465			470					475					
Cys	Leu	Gln	Ala	Gly	Met	Asn	Leu	Glu	Ala	Arg	Lys	Thr	Lys	Lys	Lys

	485		490		495
Ile Lys Gly	Ile Gln Gln Ala Thr Thr Gly Val Ser Gln Glu Thr Ser				
	500		505		510
Glu Asn Pro Gly Asn Lys Thr	Ile Val Pro Ala Thr Leu Pro Gln Leu				
	515		520		525
Thr Pro Thr Leu Val Ser	Leu Leu Glu Val Ile Glu Pro Glu Val Leu				
	530		535		540
Tyr Ala Gly Tyr Asp Ser	Ser Val Pro Asp Ser Thr Trp Arg Ile Met				
	545		550		555
Thr Thr Leu Asn Met	Leu Gly Gly Arg Gln Val Ile Ala Ala Val Lys				
	565		570		575
Trp Ala Lys Ala Ile Pro Gly Phe	Arg Asn Leu His Leu Asp Asp Gln				
	580		585		590
Met Thr Leu Leu Gln Tyr Ser	Trp Met Phe Leu Met Ala Phe Ala Leu				
	595		600		605
Gly Trp Arg Ser Tyr Arg	Gln Ser Ser Ala Asn Leu Leu Cys Phe Ala				
	610		615		620
Pro Asp Leu Ile Ile Asn	Glu Gln Arg Met Thr Leu Pro Cys Met Tyr				
	625		630		635
Asp Gln Cys Lys His Met	Leu Tyr Val Ser Ser Glu Leu His Arg Leu				
	645		650		655
Gln Val Ser Tyr Glu Glu Tyr	Leu Cys Met Lys Thr Leu Leu Leu Leu				
	660		665		670
Ser Ser Val Pro Lys Asp Gly	Leu Lys Ser Gln Glu Leu Phe Asp Glu				
	675		680		685
Ile Arg Met Thr Tyr Ile	Lys Glu Leu Gly Lys Ala Ile Val Lys Arg				
	690		695		700
Glu Gly Asn Ser Ser Gln	Asn Trp Gln Arg Phe Tyr Gln Leu Thr Lys				
	705		710		715
Leu Leu Asp Ser Met His	Glu Val Val Glu Asn Leu Leu Asn Tyr Cys				
	725		730		735
Phe Gln Thr Phe Leu Asp	Lys Thr Met Ser Ile Glu Phe Pro Glu Met				
	740		745		750
Leu Ala Glu Ile Ile Thr	Asn Gln Ile Pro Lys Tyr Ser Asn Gly Asn				
	755		760		765
Ile Lys Lys Leu Leu Phe	His Gln Lys				
	770		775		

<210> 3
 <211> 4788
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (133)..(2466)

<400> 3
 ttttttagaaa aaaaaaatat atttccctcc tgctccttct gcgttcacaa gctaagttgt 60
 ttatctcggc tgccggcggga actgcggacg gtggcgggag agcggctcct ctgccagagt 120
 tgatattcac tg atg gac tcc aaa gaa tca tta act cct ggt aga gaa gaa 171
 Met Asp Ser Lys Glu Ser Leu Thr Pro Gly Arg Glu Glu
 1 5 10
 aac ccc agc agt gtg ctt gct cag gag agg gga gat gtg atg gac ttc 219
 Asn Pro Ser Ser Val Leu Ala Gln Glu Arg Gly Asp Val Met Asp Phe
 15 20 25
 tat aaa acc cta aga gga gga gct act gtg aag gtt tct gcg tct tca 267
 Tyr Lys Thr Leu Arg Gly Gly Ala Thr Val Lys Val Ser Ala Ser Ser
 30 35 40 45
 ccc tca ctg gct gtc gct tct caa tca gac tcc aag cag cga aga ctt 315
 Pro Ser Leu Ala Val Ala Ser Gln Ser Asp Ser Lys Gln Arg Arg Leu
 50 55 60
 ttg gtt gat ttt cca aaa ggc tca gta agc aat gcg cag cag cca gat 363
 Leu Val Asp Phe Pro Lys Gly Ser Val Ser Asn Ala Gln Gln Pro Asp
 65 70 75
 ctg tcc aaa gca gtt tca ctc tca atg gga ctg tat atg gga gag aca 411
 Leu Ser Lys Ala Val Ser Leu Ser Met Gly Leu Tyr Met Gly Glu Thr
 80 85 90
 gaa aca aaa gtg atg gga aat gac ctg gga ttc cca cag cag ggc caa 459
 Glu Thr Lys Val Met Gly Asn Asp Leu Gly Phe Pro Gln Gln Gly Gln
 95 100 105
 atc agc ctt tcc tcg ggg gaa aca gac tta aag ctt ttg gaa gaa agc 507
 Ile Ser Leu Ser Ser Gly Glu Thr Asp Leu Lys Leu Leu Glu Glu Ser
 110 115 120 125
 att gca aac ctc aat agg tcg acc agt gtt cca gag aac ccc aag agt 555
 Ile Ala Asn Leu Asn Arg Ser Thr Ser Val Pro Glu Asn Pro Lys Ser
 130 135 140
 tca gca tcc act gct gtg tct gct gcc ccc aca gag aag gag ttt cca 603
 Ser Ala Ser Thr Ala Val Ser Ala Ala Pro Thr Glu Lys Glu Phe Pro
 145 150 155
 aaa act cac tct gat gta tct tca gaa cag caa cat ttg aag ggc cag 651
 Lys Thr His Ser Asp Val Ser Ser Glu Gln Gln His Leu Lys Gly Gln
 160 165 170

act ggc acc aac ggt ggc aat gtg aaa ttg tat acc aca gac caa agc Thr Gly Thr Asn Gly Gly Asn Val Lys Leu Tyr Thr Thr Asp Gln Ser 175 180 185	699
acc ttt gac att ttg cag gat ttg gag ttt tct tct ggg tcc cca ggt Thr Phe Asp Ile Leu Gln Asp Leu Glu Phe Ser Ser Gly Ser Pro Gly 190 195 200 205	747
aaa gag acg aat gag agt cct tgg aga tca gac ctg ttg ata gat gaa Lys Glu Thr Asn Glu Ser Pro Trp Arg Ser Asp Leu Leu Ile Asp Glu 210 215 220	795
aac tgt ttg ctt tct cct ctg gcg gga gaa gac gat tca ttc ctt ttg Asn Cys Leu Leu Ser Pro Leu Ala Gly Glu Asp Asp Ser Phe Leu Leu 225 230 235	843
gaa gga aac tcg aat gag gac tgc aag cct ctc att tta ccg gac act Glu Gly Asn Ser Asn Glu Asp Cys Lys Pro Leu Ile Leu Pro Asp Thr 240 245 250	891
aaa ccc aaa att aag gat aat gga gat ctg gtt ttg tca agc ccc agt Lys Pro Lys Ile Lys Asp Asn Gly Asp Leu Val Leu Ser Ser Pro Ser 255 260 265	939
aat gta aca ctg ccc caa gtg aaa aca gaa aaa gaa gat ttc atc gaa Asn Val Thr Leu Pro Gln Val Lys Thr Glu Lys Glu Asp Phe Ile Glu 270 275 280 285	987
ctc tgc acc cct ggg gta att aag caa gag aaa ctg ggc aca gtt tac Leu Cys Thr Pro Gly Val Ile Lys Gln Glu Lys Leu Gly Thr Val Tyr 290 295 300	1035
tgt cag gca agc ttt cct gga gca aat ata att ggt aat aaa atg tct Cys Gln Ala Ser Phe Pro Gly Ala Asn Ile Ile Gly Asn Lys Met Ser 305 310 315	1083
gcc att tct gtt cat ggt gtg agt acc tct gga gga cag atg tac cac Ala Ile Ser Val His Gly Val Ser Thr Ser Gly Gly Gln Met Tyr His 320 325 330	1131
tat gac atg aat aca gca tcc ctt tct caa cag cag gat cag aag cct Tyr Asp Met Asn Thr Ala Ser Leu Ser Gln Gln Gln Asp Gln Lys Pro 335 340 345	1179
att ttt aat gtc att cca cca att ccc gtt ggt tcc gaa aat tgg aat Ile Phe Asn Val Ile Pro Pro Ile Pro Val Gly Ser Glu Asn Trp Asn 350 355 360 365	1227
agg tgc caa gga tct gga gat gac aac ttg act tct ctg ggg act ctg Arg Cys Gln Gly Ser Gly Asp Asp Asn Leu Thr Ser Leu Gly Thr Leu 370 375 380	1275
aac ttc cct ggt cga aca gtt ttt tct aat ggc tat tca agc ccc agc Asn Phe Pro Gly Arg Thr Val Phe Ser Asn Gly Tyr Ser Ser Pro Ser 385 390 395	1323

atg	aga	cca	gat	gta	agc	tct	cct	cca	tcc	agc	tcc	tca	aca	gca	aca	1371
Met	Arg	Pro	Asp	Val	Ser	Ser	Pro	Pro	Ser	Ser	Ser	Ser	Thr	Ala	Thr	
		400					405					410				
aca	gga	cca	cct	ccc	aaa	ctc	tgc	ctg	gtg	tgc	tct	gat	gaa	gct	tca	1419
Thr	Gly	Pro	Pro	Pro	Lys	Leu	Cys	Leu	Val	Cys	Ser	Asp	Glu	Ala	Ser	
	415					420					425					
gga	tgt	cat	tat	gga	gtc	tta	act	tgt	gga	agc	tgt	aaa	ggt	ttc	ttc	1467
Gly	Cys	His	Tyr	Gly	Val	Leu	Thr	Cys	Gly	Ser	Cys	Lys	Val	Phe	Phe	
430					435					440				445		
aaa	aga	gca	gtg	gaa	gga	cag	cac	aat	tac	cta	tgt	gct	gga	agg	aat	1515
Lys	Arg	Ala	Val	Glu	Gly	Gln	His	Asn	Tyr	Leu	Cys	Ala	Gly	Arg	Asn	
				450					455					460		
gat	tgc	atc	atc	gat	aaa	att	cga	aga	aaa	aac	tgc	cca	gca	tgc	cgc	1563
Asp	Cys	Ile	Ile	Asp	Lys	Ile	Arg	Arg	Lys	Asn	Cys	Pro	Ala	Cys	Arg	
			465				470						475			
tat	cga	aaa	tgt	ctt	cag	gct	gga	atg	aac	ctg	gaa	gct	cga	aaa	aca	1611
Tyr	Arg	Lys	Cys	Leu	Gln	Ala	Gly	Met	Asn	Leu	Glu	Ala	Arg	Lys	Thr	
	480					485						490				
aag	aaa	aaa	ata	aaa	gga	att	cag	cag	gcc	act	aca	gga	gtc	tca	caa	1659
Lys	Lys	Lys	Ile	Lys	Gly	Ile	Gln	Gln	Ala	Thr	Thr	Gly	Val	Ser	Gln	
	495					500					505					
gaa	acc	tct	gaa	aat	cct	ggt	aac	aaa	aca	ata	gtt	cct	gca	acg	tta	1707
Glu	Thr	Ser	Glu	Asn	Pro	Gly	Asn	Lys	Thr	Ile	Val	Pro	Ala	Thr	Leu	
510					515					520					525	
cca	caa	ctc	acc	cct	acc	ctg	gtg	tca	ctg	ttg	gag	gtt	att	gaa	cct	1755
Pro	Gln	Leu	Thr	Pro	Thr	Leu	Val	Ser	Leu	Leu	Glu	Val	Ile	Glu	Pro	
				530					535					540		
gaa	gtg	tta	tat	gca	gga	tat	gat	agc	tct	gtt	cca	gac	tca	act	tggt	1803
Glu	Val	Leu	Tyr	Ala	Gly	Tyr	Asp	Ser	Ser	Val	Pro	Asp	Ser	Thr	Trp	
			545				550					555				
agg	atc	atg	act	acg	ctc	aac	atg	tta	gga	ggg	cgg	caa	gtg	att	gca	1851
Arg	Ile	Met	Thr	Thr	Leu	Asn	Met	Leu	Gly	Gly	Arg	Gln	Val	Ile	Ala	
	560					565						570				
gca	gtg	aaa	tggt	gca	aag	gca	ata	cca	ggt	ttc	agg	aac	tta	cac	ctg	1899
Ala	Val	Lys	Trp	Ala	Lys	Ala	Ile	Pro	Gly	Phe	Arg	Asn	Leu	His	Leu	
	575					580					585					
gat	gac	caa	atg	acc	cta	ctg	cag	tac	tcc	tggt	atg	ttt	ctt	atg	gca	1947
Asp	Asp	Gln	Met	Thr	Leu	Leu	Gln	Tyr	Ser	Trp	Met	Phe	Leu	Met	Ala	
590					595					600					605	
ttt	gct	ctg	gggt	tggt	aga	tca	tat	aga	caa	tca	agt	gca	aac	ctg	ctg	1995
Phe	Ala	Leu	Gly	Trp	Arg	Ser	Tyr	Arg	Gln	Ser	Ser	Ala	Asn	Leu	Leu	
			610						615					620		
tgt	ttt	gct	cct	gat	ctg	att	att	aat	gag	cag	aga	atg	act	cta	ccc	2043

Cys	Phe	Ala	Pro	Asp	Leu	Ile	Ile	Asn	Glu	Gln	Arg	Met	Thr	Leu	Pro		
			625					630						635			
tgc	atg	tac	gac	caa	tgt	aaa	cac	atg	ctg	tat	gtt	tcc	tct	gag	tta		2091
Cys	Met	Tyr	Asp	Gln	Cys	Lys	His	Met	Leu	Tyr	Val	Ser	Ser	Glu	Leu		
		640					645					650					
cac	agg	ctt	cag	gta	tct	tat	gaa	gag	tat	ctc	tgt	atg	aaa	acc	tta		2139
His	Arg	Leu	Gln	Val	Ser	Tyr	Glu	Glu	Tyr	Leu	Cys	Met	Lys	Thr	Leu		
		655				660					665						
ctg	ctt	ctc	tct	tca	gtt	cct	aag	gac	ggc	ctg	aag	agc	caa	gag	cta		2187
Leu	Leu	Leu	Ser	Ser	Val	Pro	Lys	Asp	Gly	Leu	Lys	Ser	Gln	Glu	Leu		
		670			675					680					685		
ttt	gat	gaa	att	aga	atg	acc	tac	atc	aaa	gag	cta	gga	aaa	gcc	att		2235
Phe	Asp	Glu	Ile	Arg	Met	Thr	Tyr	Ile	Lys	Glu	Leu	Gly	Lys	Ala	Ile		
			690						695					700			
gtc	aag	agg	gaa	gga	aac	tcc	agc	cag	aac	tgg	cag	cgg	ttt	tat	caa		2283
Val	Lys	Arg	Glu	Gly	Asn	Ser	Ser	Gln	Asn	Trp	Gln	Arg	Phe	Tyr	Gln		
			705					710					715				
ctg	aca	aaa	ctc	ttg	gat	tct	atg	cat	gaa	gtg	gtt	gaa	aat	ctc	ctt		2331
Leu	Thr	Lys	Leu	Leu	Asp	Ser	Met	His	Glu	Val	Val	Glu	Asn	Leu	Leu		
		720					725					730					
aac	tat	tgc	ttc	caa	aca	ttt	ttg	gat	aag	acc	atg	agt	att	gaa	ttc		2379
Asn	Tyr	Cys	Phe	Gln	Thr	Phe	Leu	Asp	Lys	Thr	Met	Ser	Ile	Glu	Phe		
		735				740					745						
ccc	gag	atg	tta	gct	gaa	atc	atc	acc	aat	cag	ata	cca	aaa	tat	tca		2427
Pro	Glu	Met	Leu	Ala	Glu	Ile	Ile	Thr	Asn	Gln	Ile	Pro	Lys	Tyr	Ser		
					755					760					765		
aat	gga	aat	atc	aaa	aaa	ctt	ctg	ttt	cat	caa	aag	tga	ctgccttaat				2476
Asn	Gly	Asn	Ile	Lys	Lys	Leu	Leu	Phe	His	Gln	Lys						
				770					775								
aagaatgggtt	gccttaaaga	aagtcgaatt	aatagctttt	attgtataaa	ctatcagttt												2536
gtcctgtaga	ggttttgttg	ttttattttt	tattgttttc	atctgttggt	ttgttttaaa												2596
tacgcactac	atgtggttta	tagagggcca	agacttgga	acagaagcag	ttgagtcgtc												2656
atcacttttc	agtgatggga	gagtagatgg	tgaaatttat	tagttaatat	atcccagaaa												2716
ttagaaacct	taatattgtg	acgtaatctc	cacagtc aaa	gaaggatggc	acctaaacca												2776
ccagtgccca	aagtctgtgt	gatgaacttt	ctcttcatac	ttttttcac	agttggctgg												2836
atgaaatttt	ctagactttc	tgttggtgta	tccccccct	gtatagttag	gatagcattt												2896
ttgattttatg	catggaaacc	tgaaaaaaag	tttacaagtg	tatatcagaa	aagggaagtt					</							

gcttgctcat tttttcttac ataatttttt attcaagtta ttgtacagct gtttaagatg 3076
ggcagctagt tcgtagcttt cccaaataaa ctctaaacat taatcaatca tctgtgtgaa 3136
aatgggttgg tgcttctaac ctgatggcac ttagctatca gaagaccaca aaaattgact 3196
caaactctca gtattcttgt caaaaaaaaa aaaaaaaaaag ctcatatttt gtatatatct 3256
gcttcagtgg agaatatat aggttgtgca aattaacagt cctaactggg atagagcacc 3316
tagtccagtg acctgctggg taaactgtgg atgatggtg caaaagacta atttaaaaaa 3376
taactaccaa gaggcctgt ctgtacctaa cgccctattt ttgcaatggc tatatggcaa 3436
gaaagctggg aaactatttg tctttcagga ccttttgaag tagtttgtat aacttcttaa 3496
aagttgtgat tccagataac cagctgtaac acagctgaga gacttttaat cagacaaagt 3556
aattcctctc actaaacttt acccaaaaaac taaatctcta atatggcaaa aatggctaga 3616
cacccatfff cacattccca tctgtcacca attggttaat ctttctgat ggtacaggaa 3676
agctcagcta ctgatttttg tgatttagaa ctgtatgtca gacatccatg tttgtaaaac 3736
tacacatccc taatgtgtgc catagagttt aacacaagtc ctgtgaatff cttcactggt 3796
gaaaattatt ttaaacaaaa tagaagctgt agtagccctt tctgtgtgca ccttaccaac 3856
tttctgtaaa ctcaaaactt aacatattta ctaagccaca agaaatttga tttctattca 3916
aggtggccaa attatttgtg taatagaaaa ctgaaaatct aatattaaaa atatggaact 3976
tctaatatat ttttatattt agttatagtt tcagatatat atcatattgg tattcactaa 4036
tctgggaagg gaagggtac tgcagcttta catgcaatff attaaaatga ttgtaaaata 4096
gcttgatatag tgtaaaataa gaatgatttt tagatgagat tgttttatca tgacatgtta 4156
tatatffffff gtaggggtca aagaaatgct gatggataac ctatatgatt tatagtttgt 4216
acatgcattc atacaggcag cgatggtctc agaaaccaa cagtttgctc taggggaaga 4276
gggagatgga gactggctct gtgtgcagtg aaggttgctg aggctctgac ccagtgaat 4336
tacagaggaa gttatcctct gcctccatt ctgaccaccc ttctcattcc aacagtgaat 4396
ctgtcagcgc aggtttagtt tactcaatct ccccttgcac taaagtatgt aaagtatgta 4456
aacaggagac aggaagggtg tgcttacatc cttaaaggca ccatctaata gcgggttact 4516
ttcacataca gccctcccc agcagttgaa tgacaacaga agcttcagaa gtttggaat 4576
agtttgcata gaggtaccag caatatgtaa atagtgcaga atctcatagg ttgccaataa 4636
tacactaatt cttttctatc ctacaacaag agtttatttc caaataaaat gaggacatgt 4696
ttttgttttc tttgaatgct tttgaatgt tatttgttat tttcagtatt ttggagaaat 4756

tatttaataa aaaaacaatc atttgctttt tg

4788

<210> 4

<211> 777

<212> PRT

<213> Homo sapiens

<400> 4

Met Asp Ser Lys Glu Ser Leu Thr Pro Gly Arg Glu Glu Asn Pro Ser
1 5 10 15

Ser Val Leu Ala Gln Glu Arg Gly Asp Val Met Asp Phe Tyr Lys Thr
20 25 30

Leu Arg Gly Gly Ala Thr Val Lys Val Ser Ala Ser Ser Pro Ser Leu
35 40 45

Ala Val Ala Ser Gln Ser Asp Ser Lys Gln Arg Arg Leu Leu Val Asp
50 55 60

Phe Pro Lys Gly Ser Val Ser Asn Ala Gln Gln Pro Asp Leu Ser Lys
65 70 75 80

Ala Val Ser Leu Ser Met Gly Leu Tyr Met Gly Glu Thr Glu Thr Lys
85 90 95

Val Met Gly Asn Asp Leu Gly Phe Pro Gln Gln Gly Gln Ile Ser Leu
100 105 110

Ser Ser Gly Glu Thr Asp Leu Lys Leu Leu Glu Glu Ser Ile Ala Asn
115 120 125

Leu Asn Arg Ser Thr Ser Val Pro Glu Asn Pro Lys Ser Ser Ala Ser
130 135 140

Thr Ala Val Ser Ala Ala Pro Thr Glu Lys Glu Phe Pro Lys Thr His
145 150 155 160

Ser Asp Val Ser Ser Glu Gln Gln His Leu Lys Gly Gln Thr Gly Thr
165 170 175

Asn Gly Gly Asn Val Lys Leu Tyr Thr Thr Asp Gln Ser Thr Phe Asp
180 185 190

Ile Leu Gln Asp Leu Glu Phe Ser Ser Gly Ser Pro Gly Lys Glu Thr
195 200 205

Asn Glu Ser Pro Trp Arg Ser Asp Leu Leu Ile Asp Glu Asn Cys Leu
210 215 220

Leu Ser Pro Leu Ala Gly Glu Asp Asp Ser Phe Leu Leu Glu Gly Asn
225 230 235 240

Ser Asn Glu Asp Cys Lys Pro Leu Ile Leu Pro Asp Thr Lys Pro Lys

545		550		555		560
Thr Thr Leu Asn Met Leu Gly Gly Arg Gln Val Ile Ala Ala Val Lys						
		565		570		575
Trp Ala Lys Ala Ile Pro Gly Phe Arg Asn Leu His Leu Asp Asp Gln						
		580		585		590
Met Thr Leu Leu Gln Tyr Ser Trp Met Phe Leu Met Ala Phe Ala Leu						
		595		600		605
Gly Trp Arg Ser Tyr Arg Gln Ser Ser Ala Asn Leu Leu Cys Phe Ala						
		610		615		620
Pro Asp Leu Ile Ile Asn Glu Gln Arg Met Thr Leu Pro Cys Met Tyr						
		625		630		635
Asp Gln Cys Lys His Met Leu Tyr Val Ser Ser Glu Leu His Arg Leu						
		645		650		655
Gln Val Ser Tyr Glu Glu Tyr Leu Cys Met Lys Thr Leu Leu Leu Leu						
		660		665		670
Ser Ser Val Pro Lys Asp Gly Leu Lys Ser Gln Glu Leu Phe Asp Glu						
		675		680		685
Ile Arg Met Thr Tyr Ile Lys Glu Leu Gly Lys Ala Ile Val Lys Arg						
		690		695		700
Glu Gly Asn Ser Ser Gln Asn Trp Gln Arg Phe Tyr Gln Leu Thr Lys						
		705		710		715
Leu Leu Asp Ser Met His Glu Val Val Glu Asn Leu Leu Asn Tyr Cys						
		725		730		735
Phe Gln Thr Phe Leu Asp Lys Thr Met Ser Ile Glu Phe Pro Glu Met						
		740		745		750
Leu Ala Glu Ile Ile Thr Asn Gln Ile Pro Lys Tyr Ser Asn Gly Asn						
		755		760		765
Ile Lys Lys Leu Leu Phe His Gln Lys						
		770		775		

CLAIMS

1. A method of determining the risk of an individual developing a metabolic disorder, the method comprising:
 - 5 (iii) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
 - (iv) determining the likelihood of the individual developing a metabolic disorder, wherein the presence of the ER22/23EK polymorphism is indicative of a low risk of developing the metabolic disorder and the absence of the
 - 10 ER22/23EK polymorphism is indicative of a high risk of developing the metabolic disorder.
2. A method according to any one of the preceding claims wherein the metabolic disorder is cardiovascular disease.
3. A method according to any one of the preceding claims wherein the
- 15 metabolic disorder is glucose intolerance or diabetes mellitus.
4. A method of predicting the longevity of an individual, the method comprising:
 - (iii) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
 - 20 (iv) determining the life expectancy of the individual, wherein the presence of the ER22/23EK polymorphism is indicative of a long life expectancy.
5. A method of determining the dose of glucocorticoid for administration to an individual in need thereof, the method comprising:
 - 25 (iii) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
 - (iv) determining whether the dose of glucocorticoid for administration to the individual should be altered compared to the standard dosage, wherein the presence of the ER22/23EK polymorphism indicates that the dosage should
 - 30 be increased.
6. A method according to claim 5 wherein the individual is suffering

from an allergic disease, an autoimmune disease, an inflammatory disorder, a neoplastic disease, graft rejection, sarcoidosis, vitamin D intoxication, thyroid storm, septic shock, cerebral edema, altitude sickness, chronic bronchitis or emphysema.

7. A method according to claim 5 or 6 wherein the glucocorticoid is selected from Hydrocortisone, Prednisone, Prednisolone, Methylprednisolone, Triamcinolone, Dexamethasone, Budesonide, Betamethasone and Beclomethasone.

8. A method according to any one of the preceding claims wherein step (i) comprises contacting a sample from the individual with a specific binding agent for the ER22/23EK polymorphism and determining whether the agent binds to the polymorphism.

9. A method according to claim 8 wherein the agent is a nucleotide binding agent.

10. A method according to claim 9 wherein the nucleotide binding agent is an oligonucleotide probe or primer.

11. A method according to claim 10 wherein the agent is a polypeptide binding agent.

12. A method according to claim 11 wherein the polypeptide binding agent is an antibody.

13. A method of determining whether a treatment regimen is suitable for an individual having a metabolic disorder, the method comprising:

(i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
(ii) determining whether the treatment is suitable for the individual, wherein the suitability of the treatment depends on the presence or absence of the ER22/23EK polymorphism.

14. A method for diagnosing and treating an individual susceptible to a metabolic disorder, the method comprising:

(iii) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene;
and

- (ii) administering to an individual having the ER22/23KK polymorphism a therapeutically effective amount of an agent which prevents or treats the metabolic disorder.

5 15. A method for increasing the life expectancy of an individual, the method comprising:

- (iv) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- (v) introducing into the individual an allele of the glucocorticoid receptor gene or a glucocorticoid receptor, wherein said gene or polypeptide does

10 not have said polymorphism.

16. A method for identifying an agent comprising:

- (ii) contacting a glucocorticoid receptor polypeptide having the sequence shown in SEQ ID NO: 1 or a fragment thereof which includes the ER22/23EK polymorphism with a test agent;
- 15 (ii) monitoring binding of the test agent to the polypeptide; and
- (vi) determining whether said test agent may increase life expectancy or be suitable for treating a metabolic disease, wherein for increasing life expectancy or treating a metabolic disease agent is one that binds to the polypeptide.

20 17. Use of a non-human animal which is transgenic for a polynucleotide having the sequence shown in SEQ ID NO: 1 in screening for agents for use in the treatment of a metabolic disorder or for increasing life expectancy.

ABSTRACTTEST

5 The invention provides a method of determining the risk of an individual developing a metabolic disorder, the method comprising:

- (i) detecting in a sample from the individual the presence or absence of the ER22/23EK polymorphism in the glucocorticoid receptor gene; and
- 10 (ii) determining the likelihood of the individual developing a metabolic disorder, wherein the presence of the ER22/23EK polymorphism is indicative of a low risk of developing the metabolic disorder and the absence of the ER22/23EK polymorphism is indicative of a high risk of developing the metabolic disorder.

Figure 1

1/1

